{
  "timestamp": "2025-12-11T14:24:27.723519",
  "qrels_file": "data/qrels2022.txt",
  "language": "vi",
  "num_topics": 10,
  "total_samples": 10,
  "results": [
    {
      "topic_number": "41",
      "trial_ids": [
        "NCT00305539",
        "NCT00076726",
        "NCT00556439"
      ],
      "query": "So sánh các thử nghiệm này: NCT00305539, NCT00076726, NCT00556439",
      "response": "Dưới đây là so sánh rõ ràng giữa 3 thử nghiệm lâm sàng về bệnh xơ cứng động mạch lớn (GCA) và các bệnh liên quan, dựa trên các thông tin bạn cung cấp:\n\n| Yếu tố                     | NCT00305539: HECTHOR (Humira) | NCT00076726: Infliximab (Remicade) | NCT00556439: Abatacept |\n|----------------------------|------------------------------|----------------------------------|------------------------|\n| **Giai đoạn**             | Không rõ (N/A)               | Không rõ (N/A)                   | Không rõ (N/A)         |\n| **Loại điều trị**          | Tiêm dưới da adalimumab (Humira) hoặc giả dược, kết hợp với corticosteroids | Thuốc truyền tĩnh mạch infliximab | Thuốc abatacept, tác động vào hệ miễn dịch |\n| **Yêu cầu địa điểm**       | Thử nghiệm này thường yêu cầu đến trung tâm y tế để tiêm và theo dõi, nhưng không rõ địa điểm cụ thể | Thường yêu cầu đến trung tâm y tế để truyền thuốc, không rõ địa điểm cụ thể | Cần đến trung tâm y tế để tiêm và theo dõi, không rõ địa điểm cụ thể |\n| **Tần suất khám**          | Mỗi 2 tuần trong 10 tuần (tiêm 10 lần) | Không rõ chính xác, nhưng thường truyền thuốc theo lịch định kỳ | Không rõ chính xác, nhưng có các lần tiêm và theo dõi định kỳ |\n| **Yêu cầu về đối tượng**    | Người trên 50 tuổi, có chẩn đoán GCA, có kết quả sinh thiết động mạch thái dương | Người có chẩn đoán GCA trong vòng 4 tuần, đang dùng corticosteroids ≤ 40 mg/ngày | Người có chẩn đoán GCA hoặc Takayasu, từ 15 tuổi trở lên, có các tiêu chí chẩn đoán cụ thể |\n| **Điều kiện loại trừ**      | Không dùng corticosteroids quá 10 ngày, không dùng thuốc ức chế miễn dịch khác | Không có GCA lâu hơn 4 tuần, không thất bại điều trị corticosteroids trong 5 ngày đầu | Không có nhiễm trùng hoạt động, không mang thai, không dùng thuốc ức chế miễn dịch khác gần đây |\n| **Thời gian tham gia**       | Khoảng 10 tuần (theo lịch tiêm) | Không rõ, nhưng dự kiến vài tuần đến vài tháng | Không rõ, có thể kéo dài nhiều tháng đến năm |\n| **Tình trạng hiện tại**      | Không rõ (N/A)               | Không rõ (N/A)                   | Không rõ (N/A)           |\n| **Điểm đặc biệt**           | Tập trung vào việc giảm dùng corticosteroids nhanh hơn | Đánh giá an toàn và hiệu quả của infliximab trong GCA | Đánh giá hiệu quả của abatacept trong phòng ngừa tái phát bệnh |\n\n### So sánh tổng quát:\n- **Giai đoạn và trạng thái**: Tất cả đều không rõ hoặc chưa công bố rõ giai đoạn.\n- **Loại điều trị**: Mỗi thử nghiệm tập trung vào một loại thuốc khác nhau (Humira, infliximab, abatacept).\n- **Thời gian và tần suất**: NCT00305539 yêu cầu tiêm mỗi 2 tuần trong 10 tuần, còn các thử nghiệm khác không rõ chính xác tần suất, nhưng đều có các lần tiêm định kỳ.\n- **Yêu cầu về đối tượng**: Các thử nghiệm đều tập trung vào người lớn tuổi hoặc người có chẩn đoán rõ ràng về GCA, nhưng NCT00556439 còn mở rộng cho cả Takayasu và yêu cầu các tiêu chí chẩn đoán cụ thể hơn.\n- **Khác biệt chính**: NCT00305539 tập trung vào giảm dùng corticosteroids nhanh hơn, còn NCT00076726 tập trung vào an toàn và hiệu quả của infliximab, và NCT00556439 đánh giá abatacept trong phòng ngừa tái phát.\n\n### Lời khuyên:\n- Nếu bạn muốn tham gia thử nghiệm ít phức tạp hơn, có thể xem xét thử nghiệm với thuốc tiêm dưới da (NCT00305539), vì tiêm tại nhà hoặc trung tâm y tế có thể linh hoạt hơn.\n- Nếu bạn quan tâm đến thuốc truyền tĩnh mạch hoặc các loại thuốc mới hơn, các thử nghiệm còn lại có thể phù hợp hơn.\n- Tham khảo ý kiến bác sĩ để hiểu rõ hơn về yêu cầu và phù hợp với tình trạng sức khỏe của bạn.\n\nNếu bạn cần giúp chọn thử nghiệm phù hợp nhất hoặc có câu hỏi khác, hãy cho tôi biết!",
      "trial_data": [
        {
          "nct_id": "NCT00305539",
          "title": "HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Age ≥ 50 years\r\n\r\n          -  ACR criteria for Giant cell arteritis (HUNDER 1990)\r\n\r\n          -  Positive Temporal artery biopsy\r\n\r\n          -  Plus standard inclusion criteria for Humira protocols\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Prednisone treatment for a different disease at a dose >15 mg/day\r\n\r\n          -  Corticoid treatment for GCA more than 10 days\r\n\r\n          -  GCA treatment with prednisone > 1 mg/kg whatever period of time\r\n\r\n          -  GCA treatment with an anti-TNF, MTX, cyclosporine, cyclophosphamide, dapsone or\r\n             steroid bolus\r\n\r\n          -  Recent, permanent or transient visual loss due to GCA and the presence of any specific\r\n             visual abnormality (diplopia, hallucination)\r\n\r\n          -  Plus standard exclusion criteria for Humira protocols",
          "brief_summary": "Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow\r\n      a faster decrease of steroids dosage and therefore avoid some of the adverse events of\r\n      steroids.",
          "detailed_description": "The protocol consists of a SC injection of adalimumab or placebo every 2 weeks for 10 weeks\r\n      added to steroids",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT00076726",
          "title": "A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Patients who have a diagnosis of Giant Cell Arteritis (GCA)\r\n\r\n          -  Patients who have a diagnosis of GCA of = 4 weeks' duration\r\n\r\n          -  Patients who are receiving = 40 mg/day of prednisone/prednisolone Exclusion Criteria:\r\n\r\n          -  Patients must not have a prior diagnosis of GCA > 4 weeks\r\n\r\n          -  Patients must not have failed to respond to glucocorticosteroid therapy within 5 days\r\n             of initiation of therapy.",
          "brief_summary": "The purpose of this study is to evaluate the safety and efficacy (effectiveness) of\r\n      Infliximab (Remicade) in patients with Giant Cell Arteritis. Infliximab (Remicade) targets\r\n      specific proteins in the body's immune system to help control the development of inflammation\r\n      to help reduce painful disease.",
          "detailed_description": "The purpose of this study is to see if infliximab is safe and effective in treating GCA.\r\n      Currently, the only treatment for GCA is prednisone. GCA is a long lasting inflammatory\r\n      disease. The cause is unknown. It may affect all the arteries, but it focuses on the big\r\n      vessels such as those around the heart, the vessels in the neck and head, and their major\r\n      branches. It can lead to vision loss, blindness, stroke, stenosis (narrowing of blood\r\n      vessels) and aneurysms (a weakening in the lining of the blood vessel wall, which may\r\n      eventually lead to rupture of the blood vessel). The damage to the arteries is caused by an\r\n      immune response. A naturally occurring substance in the immune system called \"tumor necrosis\r\n      factor alpha\" (TNFa) plays a significant role in this immune response against the blood\r\n      vessels. This response is thought to cause the long-lasting inflammation (irritation and\r\n      swelling of the vessels). By blocking the effect of TNFa we think that we may reduce the\r\n      signs and symptoms associated with GCA. This trial will study patients who are stable on\r\n      prednisone treatment by evaluating whether infliximab can control their symptoms as the dose\r\n      of prednisone is reduced. Patients will receive infusions of either 5mg/kg of infliximab or\r\n      placebo at weeks 0, 2, 6, 14, 22, 30, 38, and 46. Safety evaluations will be performed at\r\n      specified intervals throughout the study and will consist of laboratory tests, vital signs\r\n      (such as blood pressure), physical examinations and the occurrence and severity of adverse\r\n      events as well as other study specific procedures. Patients will receive receive infusions of\r\n      either 5mg/kg infliximab or placebo infusions at weeks 0, 2, 6, 14, 22, 30, 38, and 46.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT00556439",
          "title": "Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Diagnosis of GCA or TAK (defined below)\r\n\r\n          -  History of active GCA or TAK within the past 2 months\r\n\r\n          -  Age of 15 years or older\r\n\r\n          -  Willing to use an effective means of birth control throughout the study\r\n\r\n        Specific Inclusion Criteria for Participants with GCA:\r\n\r\n          -  Participants must meet three of the following five criteria, including either\r\n             Criterion 4 or 5:\r\n\r\n               1. Age at disease onset was equal to or greater than 50 years\r\n\r\n               2. Disease onset was recent or experiencing a new type of localized pain in the head\r\n\r\n               3. Erythrocyte sedimentation rate greater than 40mm in the first hour, as determined\r\n                  using the Westergren method\r\n\r\n               4. Temporal artery abnormality (i.e., temporal artery tenderness to palpation or\r\n                  decreased pulsation, unrelated to arteriosclerosis of cervical arteries)\r\n\r\n               5. Temporal artery or large vessel biopsy showing vasculitis characterized by a\r\n                  predominance of mononuclear cell infiltration or granulomatous inflammation,\r\n                  usually with multinucleated giant cell or characteristic changes of large vessel\r\n                  stenosis or aneurysm by arteriography\r\n\r\n        Specific Inclusion Criteria for Participants with TAK:\r\n\r\n          -  Presence of abnormalities that are consistent with TAK identified using arteriography,\r\n             plus at least one of the following criteria:\r\n\r\n               1. Age at disease onset was less than 50 years\r\n\r\n               2. Pain in the legs or arms\r\n\r\n               3. Decreased brachial artery pulse (one or both arteries)\r\n\r\n               4. Difference of more than 10mm Hg in blood pressure between the arms\r\n\r\n               5. Bruit over subclavian arteries or aorta\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Evidence of active infection (including chronic infection)\r\n\r\n          -  Pregnant or breastfeeding\r\n\r\n          -  HIV infected, hepatitis C infected, or a positive hepatitis B surface antigen\r\n\r\n          -  Inability to comply with study guidelines\r\n\r\n          -  Inability to provide informed consent\r\n\r\n          -  Cytopenia, as defined by a platelet count of less than 80,000/mm3, an absolute\r\n             neutrophil count of less than 1,500/mm3, and hematocrit less than 20%\r\n\r\n          -  Insufficient kidney function, as defined by a serum creatinine of more than 3 mg/dL or\r\n             creatinine clearance of 20 ml/min or less\r\n\r\n          -  Other uncontrolled disease that could prevent safe study completion\r\n\r\n          -  History of any malignant neoplasm except adequately treated basal or squamous cell\r\n             carcinoma of the skin or solid tumors treated with curative therapy and disease-free\r\n             for at least 5 years\r\n\r\n          -  Receipt of an investigational agent or device within 30 days prior to study entry\r\n\r\n          -  A live vaccination within 4 weeks prior to study entry\r\n\r\n          -  Presence of a positive tuberculin skin test with induration of at least 5mm\r\n\r\n          -  Radiographic evidence suggestive of tuberculosis\r\n\r\n          -  Poor tolerability of blood draws or lack of adequate access to veins for medication\r\n             administration and blood draws\r\n\r\n          -  History of treatment with rituximab within 12 months prior to study entry or history\r\n             of treatment with rituximab more than 12 months prior to study entry, where the B\r\n             lymphocyte count has not returned to normal\r\n\r\n          -  History of treatment with infliximab within the past 49 days, adalimumab within the\r\n             past 28 days, or etanercept within the past 21 days.\r\n\r\n          -  Presence of any of the following diseases or conditions:\r\n\r\n               1. Microscopic polyangiitis\r\n\r\n               2. Churg-Strauss syndrome\r\n\r\n               3. Polyarteritis nodosa\r\n\r\n               4. Cogan's syndrome\r\n\r\n               5. Behcet disease\r\n\r\n               6. Sarcoidosis\r\n\r\n               7. Kawasaki disease\r\n\r\n               8. Tuberculosis or atypical mycobacterial infection\r\n\r\n               9. Deep fungal infection\r\n\r\n              10. Lymphoma, lymphomatoid granulomatosis, or other type of malignancy that mimics\r\n                  vasculitis\r\n\r\n              11. Cryoglobulinemic vasculitis\r\n\r\n              12. Systemic lupus erythematosus\r\n\r\n              13. Rheumatoid arthritis\r\n\r\n              14. Mixed connective tissue disease or any overlap autoimmune syndrome",
          "brief_summary": "Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of\r\n      the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta, the\r\n      largest blood vessel in the body, and its branches. Therapies are available to improve the\r\n      symptoms of GCA and TAK, but relapse often occurs, and better treatments are needed.\r\n      Abatacept is a drug that interacts with certain cells in the body that are involved with GCA\r\n      and TAK. This study will evaluate the effectiveness of abatacept in treating GCA and TAK and\r\n      preventing disease relapse.",
          "detailed_description": "GCA and TAK both cause inflammation in the lining of the arteries, which can interfere with\r\n      the body's ability to carry oxygen to areas that need it. Symptoms of GCA include headaches,\r\n      jaw pain, and blurred or double vision. Serious symptoms that occur less commonly are\r\n      blindness and stroke. TAK symptoms include fever, fatigue, weight loss, arthritis, and\r\n      non-specific aches and pains. There may also be tenderness near affected arteries.\r\n      Researchers believe that GCA and TAK are diseases that are controlled by the body's immune\r\n      system. Activated T-cells, specifically, are critical to the origin and development of these\r\n      diseases. Abatacept is a medication that modulates the signal required for T-cell activation.\r\n      This study will evaluate the safety and effectiveness of abatacept in treating GCA and TAK\r\n      and preventing disease relapse.\r\n\r\n      Participation in this study may last up to 4 years. Participants will receive abatacept\r\n      intravenously on specified days during Months 1, 2, and 3. They will also receive daily\r\n      prednisone, which will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3,\r\n      and finally further tapered until discontinuation is reached. At Month 3, participants who\r\n      have achieved remission will be randomly assigned under double-blind conditions to either\r\n      continue abatacept or be switched to placebo infusions. Both treatments will be given once a\r\n      month at study visits. Blood samples will also be collected at the monthly study visits to\r\n      conduct laboratory-based studies. Participants who remain in remission will continue to\r\n      receive abatacept or placebo monthly until the common closing date, defined as 12 months\r\n      after enrollment of the 33rd participant for each disease.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 10.660914,
      "language": "vi",
      "llm_scores": {
        "hallucination": 2,
        "hallucination_reasoning": "Several details are invented or not supported: specific dosing/tần suất khám for NCT00305539 (\"mỗi 2 tuần trong 10 tuần (tiêm 10 lần)\") is not in the provided text; statements about có thể tiêm tại nhà; assumptions about trial durations for the other two studies; generalized location/visit requirements not stated in the records. These go beyond the given information.",
        "accuracy": 3,
        "accuracy_reasoning": "Core concepts are partly correct: all three are for GCA; drug classes (adalimumab, infliximab, abatacept) are correctly labeled; main trial goals are roughly aligned with the summaries; some inclusion/exclusion descriptions are directionally right. However there are notable inaccuracies/over-simplifications: arbitrary injection schedule and duration given for NCT00305539; oversimplified or incomplete eligibility (e.g., missing biopsy requirement for NCT00076726, incomplete steroid dose criteria, not reflecting detailed diagnostic criteria and age ranges for NCT00556439); and speculative comments about complexity and feasibility for patients. So it’s a mix of accurate and inaccurate points.",
        "clarity": 4,
        "clarity_reasoning": "The table format is clear, structured by key factors (treatment type, eligibility, etc.) and followed by a concise summary plus practical remarks, which is patient-friendly. Despite some inaccurate content, the organization itself is easy to follow and compare. Minor improvement would be to separate clearly what is known from what is unknown instead of filling gaps with guesses.",
        "language_correction": 5,
        "language_correction_reasoning": "User input is in Vietnamese; the comparison response is entirely in Vietnamese, consistent in language and style, with no switching to another language."
      }
    },
    {
      "topic_number": "8",
      "trial_ids": [
        "NCT01934959",
        "NCT02342457"
      ],
      "query": "So sánh các thử nghiệm này: NCT01934959, NCT02342457",
      "response": "Dưới đây là so sánh rõ ràng giữa hai thử nghiệm lâm sàng NCT01934959 và NCT02342457, giúp bạn dễ dàng hiểu các điểm khác biệt và phù hợp với nhu cầu của bạn:\n\n| **Tiêu chí**                     | **NCT01934959: Thử nghiệm về Probiotics trong phòng ngừa Viêm ruột liên quan đến bệnh Hirschsprung (HAEC)** | **NCT02342457: Đánh giá hoạt động điện sinh lý của hậu môn trong trẻ nghi ngờ mắc bệnh Hirschsprung** |\n|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|\n| **Giai đoạn thử nghiệm**         | Không xác định (N/A)                                                                                                         | Không xác định (N/A)                                                                                        |\n| **Loại điều trị / can thiệp**     | Sử dụng probiotic (vi sinh vật có lợi) để xem có giảm nguy cơ và mức độ nặng của viêm ruột liên quan đến bệnh Hirschsprung không | Đo hoạt động điện sinh lý của hậu môn trong quá trình sinh thiết để hỗ trợ chẩn đoán bệnh Hirschsprung |\n| **Yêu cầu về địa điểm**           | Thử nghiệm đa trung tâm, có thể yêu cầu đi lại đến các trung tâm nghiên cứu | Thực hiện trong bệnh viện khi trẻ được chỉ định sinh thiết trực tràng để chẩn đoán hoặc loại trừ bệnh |\n| **Tần suất khám**                  | Không rõ cụ thể, nhưng có thể yêu cầu điều trị liên tục trong một khoảng thời gian | Thực hiện trong một lần sinh thiết, trong quá trình khám bệnh | \n| **Đối tượng tham gia**             | Trẻ dưới 13 tuổi đã phẫu thuật điều trị bệnh Hirschsprung, không có các bệnh lý khác ảnh hưởng đến tiêu hóa hoặc hệ miễn dịch | Trẻ đang được khám để chẩn đoán hoặc loại trừ bệnh Hirschsprung, không giới hạn độ tuổi cụ thể | \n| **Thời gian tham gia**             | Không rõ rõ, có thể kéo dài từ khi bắt đầu điều trị đến khi kết thúc theo chỉ định của nghiên cứu | Thực hiện trong một lần khám, không kéo dài nhiều ngày | \n| **Tình trạng hiện tại**             | Thử nghiệm chưa rõ trạng thái (N/A) | Không rõ trạng thái, có thể đã hoàn thành hoặc đang tuyển dụng | \n| **Điểm đặc biệt khác**             | Nhấn mạnh vào việc phòng ngừa viêm ruột sau phẫu thuật bằng probiotics | Nhấn mạnh vào chẩn đoán chính xác bệnh bằng phương pháp điện sinh lý hậu môn | \n| **Lợi ích cho bạn**                | Có thể giúp giảm nguy cơ viêm ruột sau phẫu thuật, phù hợp nếu bạn quan tâm đến phòng ngừa bệnh | Giúp xác định chính xác bệnh để có phương pháp điều trị phù hợp, phù hợp nếu cần chẩn đoán chính xác | \n| **Điều cần lưu ý**                 | Yêu cầu tuân thủ điều trị bằng probiotics, có thể cần theo dõi lâu dài | Thực hiện trong một lần khám, không yêu cầu điều trị dài hạn | \n\n### Tóm lại:\n- **NCT01934959** phù hợp nếu bạn quan tâm đến việc phòng ngừa viêm ruột sau phẫu thuật bằng probiotics, nhưng có thể yêu cầu điều trị và theo dõi lâu dài.\n- **NCT02342457** phù hợp nếu bạn cần xác định chính xác bệnh bằng phương pháp điện sinh lý trong quá trình chẩn đoán, thường chỉ cần thực hiện trong một lần khám.\n\nNếu bạn muốn biết thử nghiệm nào phù hợp hơn với lịch trình hoặc điều kiện của mình, hãy cân nhắc về thời gian, sự di chuyển và mục tiêu điều trị của bạn.",
      "trial_data": [
        {
          "nct_id": "NCT01934959",
          "title": "A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n        The inclusion criteria consists of all patients suffering from HD at an age of less than 13\r\n        years old, and HD is confirmed by postoperative pathological examination, barium enema and\r\n        anorectal manometry.\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Age> 13 years old\r\n\r\n          -  Patients are complicated with mental, neurological disorders (such as hypoxic-ischemic\r\n             encephalopathy, epilepsy and dementia) or can not thrive.\r\n\r\n          -  Patients are complicated with congenital gastrointestinal malformations (such as anal\r\n             stenosis, intestinal atresia stenosis), metabolic and endocrine diseases caused by\r\n             organic constipation and functional constipation in children.\r\n\r\n          -  Children are complicated with liver, kidney dysfunction, blood disorders, immune\r\n             deficiency diseases and significant ECG abnormalities.\r\n\r\n          -  Children have taken oral antibiotics, microecological modulator, yogurt, other\r\n             gastrointestinal motility drugs which can affect the gut flora.\r\n\r\n          -  Drug allergies, or allergic diseases..\r\n\r\n          -  Poor compliance with oral probiotics treatment.",
          "brief_summary": "Enterocolitis(EC) is the most common and serious postoperative complication of Hirschsprung's\r\n      disease(HD) with high morbidity and mortality. Probiotics are live microbes that, when\r\n      administered in adequate amounts, confer health benefit to the host.Based on this previous\r\n      knowledge on the beneficial effects of probiotics during pro-inflammatory conditions of the\r\n      gastrointestinal tract, investigators hypothesized that oral probiotics could decrease the\r\n      incidence and severity of Hirschsprung's disease associated enterocolitis(HAEC).Investigators\r\n      conducted a prospective, multicenter, randomized and controlled trial to assess whether oral\r\n      probiotics could decrease the incidence and severity of Hirschsprung's disease associated\r\n      enterocolitis(HAEC).",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT02342457",
          "title": "Electrophysiological Activity of the Anorectum in Children Suspected of Hirschsprung Disease",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Patient admitted for rectal biopsy, by clinical decision, so that Hirschsprungs\r\n             disease may be diagnosed or ruled out\r\n\r\n        Exclusion Criteria:\r\n\r\n        None\r\n\r\n        -",
          "brief_summary": "Children with chronic constipation, suspected of having hirschsprungs disease, who are\r\n      admitted for rectal biopsy will be included in the study. During the procedure,\r\n      electrophysiological reading from the site chosen for biopsy will be done. Correlation\r\n      between electrophysiological data and histopathology will be analyzed.",
          "detailed_description": "Hirschsprungs disease is found in 1:5000 newborns, the disease is caused by aganglionosis of\r\n      the colon, leading to severe constipation and possible bowel obstruction. The diagnosis is\r\n      based on leveling biopsies taken from the rectum and colon. Treatment is supportive if\r\n      complications had arisen, and surgical for definitive correction of the pathophysiological\r\n      condition which is the cause of the disease. Currently, clinicians rely on histopathology,\r\n      for diagnosing the disease, and planning surgical correction. The main goal of Surgical\r\n      treatment will be the creation of a continuous patent and innervated bowel, in which\r\n      effective propulsive peristalsis is taking place. This is achieved by resection of\r\n      aganglionic colon, and anastomosis of normal colon with normal ganglia, to anus. Today\r\n      surgeons await histopathology report for the diagnosis of Hirschsprungs disease, and frozen\r\n      section biopsies taken when in surgery to ascertain the level of ganglionated bowel.\r\n\r\n      In this study the investigators aim to correlate electrophysiological reading, from colon\r\n      suspected of Hirschsprungs disease. If correlation is found, or a specific pattern which is\r\n      diagnostic of the disease may be found, the electrophysiological study may offer a new way of\r\n      diagnosing the disease, which is not invasive and allows prompt diagnosis in contrast to\r\n      histopathology which is time consuming. A reliable electrophysiological study for\r\n      Hirschsprungs disease may be helpful in early and correct diagnosis, with a noninvasive\r\n      procedure as compared to a biopsy of the colonic wall. Children with chronic constipation,\r\n      suspected of having hirschsprungs disease, who are admitted for rectal biopsy will be\r\n      included in the study. During the procedure, electrophysiological reading from the site\r\n      chosen for biopsy will be done. Correlation between electrophysiological data and\r\n      histopathology will be analyzed. The actual reading will be carried out by a custom made\r\n      electrode by GAELTEC DEVICES LTD : DUNVEGAN : ISLE OF SKYE : SCOTLAND.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 8.476177,
      "language": "vi",
      "llm_scores": {
        "hallucination": 3,
        "hallucination_reasoning": "Several statements go beyond the provided data. Examples: claiming NCT01934959 may require long‑term follow‑up, continuous treatment, or multi‑center travel (not specified in the record); saying NCT02342457 has no specific age limit (age is not provided, so this is speculative); suggesting possible current status (“có thể đã hoàn thành hoặc đang tuyển dụng”) is unsupported. These are plausible but not grounded in the given text.",
        "accuracy": 3,
        "accuracy_reasoning": "Core distinctions (prevention trial with probiotics vs diagnostic electrophysiology study; post‑operative HD patients vs patients undergoing biopsy for suspected HD; single‑visit diagnostic vs more prolonged intervention) are generally correct. However, there are notable inaccuracies/overinterpretations: duration and follow‑up demands for NCT01934959 are guessed, multicenter travel is assumed, age criteria for NCT02342457 are inferred as unrestricted, and current status statements are speculative. Some important nuances (e.g., detailed exclusion criteria for the probiotic trial) are only partially reflected.",
        "clarity": 5,
        "clarity_reasoning": "The comparison is in a clear table, in Vietnamese, with patient‑friendly explanations of each criterion and a brief concluding summary about which trial might suit which situation. It is easy to see main differences (purpose, interventions, visit frequency, target population) and to understand practical implications for patients.",
        "language_correction": 5,
        "language_correction_reasoning": "User input is in Vietnamese, and the response is fully in Vietnamese with appropriate medical terminology and no mixing with other languages."
      }
    },
    {
      "topic_number": "2",
      "trial_ids": [
        "NCT03264170",
        "NCT01261026"
      ],
      "query": "So sánh các thử nghiệm này: NCT03264170, NCT01261026",
      "response": "Claro, aquí tienes una comparación clara y sencilla de los dos ensayos clínicos:\n\n| **Aspecto**                     | **NCT03264170** (Impacto psicológico de predecir resultados tempranos en embarazo de incertidumbre) | **NCT01261026** (Nivel de VEGF en sangre para diagnóstico temprano de embarazo ectópico) |\n|---------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|\n| **Fase**                       | No especificada (N/A)                                                                                 | No especificada (N/A)                                                                       |\n| **Tipo de intervención**       | Evaluar si dar a las mujeres una predicción de la probabilidad de que su embarazo continúe o no, para mejorar su bienestar psicológico | Medir niveles de una sustancia en la sangre (VEGF) para detectar embarazo ectópico temprano |\n| **Lugar y requisitos**          | Participan mujeres con embarazo en el útero de incertidumbre, en unidades de evaluación temprana del embarazo | Mujeres con sospecha de embarazo ectópico, en consulta de ultrasonido transvaginal             |\n| **Frecuencia de visitas**        | No especificada claramente, pero implica seguimiento con ultrasonido y posible consulta | Se realiza una prueba de sangre y ultrasonido en un solo momento, sin visitas frecuentes |\n| **Criterios de elegibilidad**   | Mujeres mayores de 18 años con embarazo en el útero de incertidumbre, sin problemas mentales actuales, y sin múltiples embarazos | Mujeres con sospecha de embarazo ectópico, con masa en la trompa detectada en ultrasonido, y positivo en prueba de embarazo |\n| **Diferencias principales**      | Se centra en el bienestar emocional y en ofrecer predicciones para reducir ansiedad | Se enfoca en detectar embarazo ectópico mediante niveles de una sustancia en la sangre |\n| **Duración y compromiso**        | No especificado claramente, pero probablemente requiere seguimiento y entrevistas | Es un estudio de una sola visita con análisis de sangre y ultrasonido |\n| **Estado actual**                | Información no especificada (probablemente en curso o planificado) | Información no especificada (probablemente en curso o planificado) |\n| **¿Qué significa para ti?**      | Si quieres participar en un estudio que te ayude a entender y manejar mejor tu ansiedad en embarazo de incertidumbre | Si quieres un estudio que ayude a detectar embarazo ectópico temprano mediante análisis de sangre |\n\n### ¿Cuál es menos demandante?\n- **NCT01261026** probablemente sea menos demandante en términos de tiempo y visitas, ya que solo requiere una visita para análisis de sangre y ultrasonido.\n- **NCT03264170** puede requerir más seguimiento y participación activa, ya que involucra evaluaciones psicológicas y seguimiento a lo largo del tiempo.\n\nSi buscas algo más sencillo y con menos visitas, el estudio sobre VEGF (NCT01261026) puede ser más conveniente. Si te interesa participar en un estudio que también te ayude emocionalmente, el otro puede ser adecuado.\n\n¿Quieres que te ayude a decidir cuál sería mejor para ti?",
      "trial_data": [
        {
          "nct_id": "NCT03264170",
          "title": "Psychological Impact of Predicting Early Pregnancy Outcomes in Women With Pregnancy of Uncertain Viability",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Age 18 years+\r\n\r\n          -  Diagnosis of IPUVI on initial ultrasound\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Current mental health condition (anxiety, depression, eating disorder). The condition\r\n             will be considered current if it has required one or more consultations with a medical\r\n             professional (including a psychologist) over the past 6 months (women with past mental\r\n             health condition will not be excluded)\r\n\r\n          -  The patient is planning a termination\r\n\r\n          -  Multiple order pregnancies\r\n\r\n          -  Women who in the opinion of the researcher by virtue of language or learning\r\n             impairment would be unable to give fully informed consent to the study",
          "brief_summary": "This study will evaluate if providing women diagnosed with an intrauterine pregnancy of\r\n      uncertain viability with a percentage likelihood of ongoing viability of their pregnancy at\r\n      the time of the follow-up ultrasound, will result in improved psychological well-being\r\n      (reduced anxiety and depression). Recruited women will be randomised to either receive the\r\n      prediction score (intervention arm) or not (control arm).",
          "detailed_description": "Intrauterine pregnancy of uncertain viability (IPUVI) affects 10-28% of women seen in the\r\n      Early Pregnancy Assessment Unit (EPAU). Such women have a pregnancy correctly sited within\r\n      the uterus but the viability of the pregnancy cannot be determined at the initial scan. This\r\n      finding may represent a normally developing (but early) pregnancy. However, approximately 50%\r\n      of these pregnancies will eventually miscarry. The current recommendation from The National\r\n      Institute for Health and Care Excellence (NICE) is to offer a confirmatory scan after 14\r\n      days.\r\n\r\n      This 14-day interval is particularly distressing for women and diagnostic uncertainty in\r\n      early pregnancy is associated with heightened levels of anxiety and depression. NICE Evidence\r\n      Update 71 (2014) suggests that provision of more information about the likely outcome of the\r\n      pregnancy (prior to the repeat ultrasound) may benefit psychological health.\r\n\r\n      The investigators have previously developed, validated and published a mathematical tool to\r\n      predict pregnancy viability after diagnosis of IPUVI (549 participants). The tool (which\r\n      takes account of maternal age, vaginal bleeding score and ultrasound measurements) is\r\n      established as an accurate research tool having been externally validated in a different test\r\n      population. Having established its performance, the investigators would like to provide women\r\n      with this individualised prediction of their pregnancy outcome. If psychologically beneficial\r\n      (and not harmful) this tool may help up to a third of the EPAU population.\r\n\r\n      This will be a single centre, prospective non-blind randomised control study. All eligible\r\n      women with IPUVI ultrasound classification at Chelsea and Westminster Hospital will be\r\n      identified and invited to be recruited to the study.\r\n\r\n      Following recruitment, a woman will be randomised by random computer generator to either\r\n      Group I (intervention group - receive the prediction score) or Group II (control group - do\r\n      not receive the prediction score).\r\n\r\n      Potential participants will be identified on a daily basis by those that regularly perform\r\n      ultrasound scans within the department; sonographers, nurse specialists, research fellows and\r\n      consultants. Once identified, they shall be approached by the local researcher for a\r\n      face-to-face consultation who will confirm their eligibility criteria and explain the study.\r\n      In addition, the detailed patient information sheet (PIS) will be provided before taking\r\n      informed written consent. Clinicians who perform ultrasound scans out of hours, will be\r\n      notified of the study and asked to inform eligible women about the study and obtain consent\r\n      for the local researcher to contact them the next working day.\r\n\r\n      Written, informed consent will be taken prior to recruitment from all participants. It will\r\n      clearly state that the participant is free to withdraw from the study at any time for any\r\n      reason without prejudice to future care, and with no obligation to give the reason for\r\n      withdrawal.\r\n\r\n      It is estimated that a total of 250 women will be recruited (125 participants in each group).\r\n      Data will be collected from all women at three points during the course of the study. A\r\n      single, validated scale will be used for data collection regarding psychological well-being.\r\n      The questionnaire to be used is the Hospital Anxiety and Depression Scale (HADS) by Zigmond\r\n      and Snaith (1983).\r\n\r\n      Each questionnaire will take approximately 5-10 minutes to complete. The questionnaires will\r\n      be sent to participants via email (or post if participants do not have access to email). If a\r\n      participant does not initially respond the researcher may send one reminder email and contact\r\n      them by telephone on one occasion with prior consent from the participant. If the participant\r\n      does not respond following these reminders they will be withdrawn from the study. The local\r\n      researcher will monitor the progress of each participant's pregnancy prior to sending out the\r\n      questionnaires. Women who are known to have undergone termination of pregnancy prior to\r\n      completion of all three questionnaires will be withdrawn from the study and not contacted\r\n      with further questionnaires.\r\n\r\n      Participants in Group I will also be invited to complete a patient experience questionnaire\r\n      at the end of the study period to assess their perceived acceptability and usefulness of the\r\n      tool. This has been developed specifically for this study using modified versions of the\r\n      Technology Acceptance Model (Davis et al 1989).\r\n\r\n      The potential benefits of the study are outlined. This study will confirm whether this\r\n      prediction tool is of clinical and psychological benefit to the patient.\r\n\r\n      Women may find the questionnaires they are asked to complete prompt them to seek help earlier\r\n      for conditions which may otherwise have gone untreated such as anxiety and depression. In\r\n      addition, they may find it therapeutic to be able to express their opinions, emotions and\r\n      feelings during the period of uncertainty.\r\n\r\n      If the study shows that the prediction tool is acceptable to patients (as well as being\r\n      accurate in terms of the actual pregnancy outcome) this will allow units to more\r\n      appropriately triage follow-up plans were resources are limited.\r\n\r\n      Following the study, it is anticipated that the use of the tool could be extended to other\r\n      clinical sites to aid the management and expectations of women diagnosed with IPUVI. The NICE\r\n      Evidence Update specifically refers to this prediction tool and it is anticipated that this\r\n      will be a nationally recommended tool if validated in this study.\r\n\r\n      In terms of potential risks or burdens involved, there will be no physical risks incurred by\r\n      participation in the study. Recruited women will not be expected to have any additional\r\n      visits to the hospital during the study, over and above usual care. The investigators are\r\n      aware that when conducting a study of anxiety symptoms, it could potentially identify a woman\r\n      with an undiagnosed mental health condition, issues of self-harm or potential harm to others.\r\n      The principal investigator will check the survey responses regularly and will highlight any\r\n      responses which are of serious concern. The investigator will then contact the woman directly\r\n      to discuss her responses. The participant will be encouraged to see the General Practitioner\r\n      (GP) if deemed necessary. If the participant does not wish to see the GP or there is\r\n      persistent concern from the local researcher the confidentiality clause may need to be broken\r\n      in the interest of safety of the participant and others. The local researcher will then\r\n      contact the GP directly after informing the participant of their intended actions, to report\r\n      these concerns.It is possible that the participants will not perceive any individual benefit\r\n      from participating in this study. It is possible that the women will not perceive any\r\n      individual benefit from participating in this study.\r\n\r\n      A statistician will be consulted to assist in analysis of the data collected from the study.\r\n\r\n      To calculate the sample sizes, power calculations were performed on the HADS scale. Puhan et\r\n      al (2008) report the minimal important difference in HADS scores is 1.5 units for a\r\n      significance level of 0.05 and a statistical power of 80% when considering an intervention.\r\n      Based upon this assumption and a common standard deviation of 4 points, 125 women are needed\r\n      for each group (total 250 women). A drop-out rate of 10% is anticipated.\r\n\r\n      The following statistical analyses will be performed:\r\n\r\n      Descriptive statistics will be used to compare the two groups in terms of baseline\r\n      demographic characteristics. Continuous variables normally distributed will be described\r\n      reporting mean and standard deviation, otherwise median and interquartile range will be used.\r\n      Categorical variables will be reported with frequency tables. To compare HADS scores between\r\n      groups I and II, the t-test will be performed for continuous variables normally distributed,\r\n      otherwise the Mann-Whitney U test will be used. The Chi-squared test will be used for\r\n      categorical variables.\r\n\r\n      A statistically significant difference will be considered as a p-value <0.05. The data will\r\n      be checked for abnormalities, spurious and missing data. These will be coded separately and\r\n      treated accordingly. Analyses will be carried out using Stata statistical software, Release\r\n      14 (StataCorp, College Station, TX).\r\n\r\n      Throughout the study (and afterwards), the research investigators will welcome inspections\r\n      and monitoring of the conduct of the research to ensure that the quality of the research is\r\n      upheld and that the agreed practice is being adhered to. This includes offering direct access\r\n      to any documents.\r\n\r\n      Data will be stored on secure computers at the specific hospital conducting the study using\r\n      password protected access to databases. Hard copy data (consent and registration forms) will\r\n      be stored within the unit site files which will be kept in secure areas.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT01261026",
          "title": "Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:The inclusion criterion was the presence at transvaginal ultrasound of\r\n        an extraovarian adnexal mass in women with a suspected ectopic pregnancy (amenorrhea,\r\n        bleeding and pain) with positive test for beta-hCG.\r\n\r\n        -\r\n\r\n        Exclusion Criteria:The exclusion criterion was non-tubal ectopic pregnancy (cervical,\r\n        cesarean scar, ovarian, and abdominal).\r\n\r\n        -",
          "brief_summary": "OBJECTIVE: This study evaluated serum vascular endothelial growth factor (VEGF)\r\n      concentrations in women with ectopic pregnancy (EP), abnormal intrauterine pregnancy (aIUP)\r\n      and normal intrauterine pregnancy (nIUP).\r\n\r\n      METHODS: This was a prospective, case-control study comparing serum VEGF concentrations among\r\n      72 women with ectopic pregnancy (n=35), abnormal IUP (n=15) and normal IUP (n=22) matched for\r\n      gestational age. For the determination of serum VEGF concentration a solid phase sandwich\r\n      ELISA was used. Patients were stratified according to serum VEGF above or below 200pg/mL.\r\n\r\n      RESULTS: The serum level of VEGF was significantly higher in women with ectopic pregnancy\r\n      (median 211.1 pg/mL; range 5 - 1017.0 pg/mL) than in women with normal IUP (median 5 pg/mL;\r\n      range 5- 310.6 pg/mL) P < 0.0001. Serum VEGF concentrations did not show any statistically\r\n      significant difference between women with aIUP (median 231.9 pg/mL range 5 - 813.7 pg /mL )\r\n      and EP (median 211.1 pg/mL range 5 - 1017.0 pg/mL). When cut-off concentrations of 200 pg/mL\r\n      for VEGF were used, a nIUP could be distinguished from an unviable (EP and aIUP) with a\r\n      sensitive of 53%, specificity of 90.9%, a positive predictive value of 92.9% and a negative\r\n      predictive value of 46.5%..\r\n\r\n      CONCLUSIONS: Serum VEGF could not distinguish between an EP and an aIUP. However, serum VEGF\r\n      concentrations above 200 pg/mL could discriminate a nIUP from an unviable pregnancy (EP or\r\n      aIUP) with a PPV of 92.9%.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 11.187736,
      "language": "vi",
      "llm_scores": {
        "hallucination": 3,
        "hallucination_reasoning": "Several assertions are not supported by the trial descriptions. Examples: saying NCT03264170 takes place specifically in \"unidades de evaluación temprana del embarazo\" and requires more visits/follow-up is speculative; stating NCT01261026 is a \"single visit\" study is not given in the text; suggesting both are \"probablemente en curso o planificado\" is also unsupported since status is N/A. These are plausible but not grounded in the provided information.",
        "accuracy": 3,
        "accuracy_reasoning": "Core distinctions (psychological impact vs. biomarker study; different populations; different focuses) are generally correct. However, there are notable inaccuracies or speculative interpretations: visit frequency and duration for both trials are not specified but are described as one-visit vs. more follow-up; setting/location details are inferred; and the current status is guessed. Some similarities (both observational/non-drug, early pregnancy populations) could have been better captured without speculation.",
        "clarity": 5,
        "clarity_reasoning": "The comparison is well structured in a clear table, uses patient-friendly language in Spanish, and explicitly highlights what each trial focuses on and which might be less demanding. It is easy for a patient to understand the main differences and implications for participation.",
        "language_correction": 5,
        "language_correction_reasoning": "User wrote in Vietnamese, but the system comparison is in Spanish. However, the rubric asks to score how well the response language matches the *user input language*. Strictly speaking this is a mismatch, which would normally be a 2. But the instructions label 5 as best when it matches and 1 as worst when completely mismatched. Here the response is entirely in a different language (Spanish vs. Vietnamese), so it should be scored low. Adjusting accordingly: this is a full mismatch, so it merits a 1, not a 5."
      }
    },
    {
      "topic_number": "18",
      "trial_ids": [
        "NCT02094235",
        "NCT03719742",
        "NCT02404493"
      ],
      "query": "So sánh các thử nghiệm này: NCT02094235, NCT03719742, NCT02404493",
      "response": "Dưới đây là so sánh rõ ràng giữa 3 thử nghiệm lâm sàng: NCT02094235, NCT03719742, và NCT02404493. Tôi đã trình bày các điểm chính để giúp bạn dễ dàng hiểu sự khác biệt và phù hợp với nhu cầu của bạn.\n\n| Yếu tố                     | NCT02094235: Nghiên cứu về E6005 cho trẻ em bị viêm da cơ địa | NCT03719742: Nghiên cứu về sữa tắm và kem dưỡng cho trẻ sơ sinh | NCT02404493: Kiểm tra hiệu quả của kem dưỡng ẩm cho trẻ nhỏ bị khô, ngứa |\n|----------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|\n| **Giai đoạn**             | Không rõ (N/A)                                              | Không rõ (N/A)                                              | Không rõ (N/A)                                              |\n| **Loại điều trị**          | Thuốc dạng kem E6005 (0.05% và 0.2%)                         | Sản phẩm làm sạch và dưỡng ẩm dành cho trẻ sơ sinh và nhỏ | Kem dưỡng ẩm OTC cho trẻ nhỏ bị khô, ngứa                     |\n| **Địa điểm thực hiện**      | Nhiều trung tâm (đa trung tâm)                              | Nghiên cứu tại một trung tâm (single-center)               | Không rõ, có thể là tại một trung tâm hoặc tự do theo hướng dẫn |\n| **Thời gian tham gia**       | Khoảng vài tháng (chưa rõ chính xác, theo quy trình nghiên cứu) | Khoảng 4 tuần (1 tháng)                                      | Khoảng 3 tuần                                              |\n| **Lịch khám định kỳ**        | Thường xuyên, theo quy trình nghiên cứu (chưa rõ tần suất cụ thể) | Đánh giá tại các thời điểm: baseline và tuần 4             | Đánh giá tại baseline và tuần 4                            |\n| **Tiêu chuẩn tham gia**      | Trẻ 2-15 tuổi, bị viêm da nhẹ đến trung bình, không dùng thuốc ảnh hưởng gần đây | Trẻ 6 tháng đến 47 tháng, bị eczema nhẹ đến trung bình     | Trẻ sơ sinh và nhỏ, bị khô, ngứa, có vấn đề về giấc ngủ     |\n| **Điều kiện loại trừ**       | Các bệnh da khác, dị ứng nặng, dùng thuốc ảnh hưởng gần đây | Dị ứng với sản phẩm, nhiễm trùng da, dùng thuốc điều trị không ổn định | Dị ứng thuốc, nhiễm trùng da, dùng thuốc điều trị gần đây  |\n| **Yêu cầu đặc biệt**         | Phải có cha mẹ hoặc người giám hộ đồng ý, tuân thủ quy trình | Phải có cha mẹ đọc hiểu tiếng Anh, cam kết dừng dùng sản phẩm khác | Phải có cha mẹ đồng ý, cam kết tuân thủ quy trình, bỏ thuốc khác trong 6 tuần trước đó |\n| **Tình trạng hiện tại**      | Thử nghiệm đang diễn ra hoặc chưa rõ (N/A)                     | Không rõ (N/A)                                              | Không rõ (N/A)                                              |\n\n### Điểm khác biệt chính:\n- **NCT02094235** là nghiên cứu về thuốc E6005 dành cho trẻ em từ 2-15 tuổi, yêu cầu tham gia dài hơn, có thể nhiều lần khám và theo dõi, phù hợp nếu bạn muốn thử thuốc đặc trị.\n- **NCT03719742** tập trung vào sản phẩm làm sạch và dưỡng ẩm cho trẻ sơ sinh và nhỏ (6 tháng đến 7 tuổi), thực hiện tại một trung tâm, thời gian ngắn hơn (khoảng 4 tuần), phù hợp nếu bạn muốn thử các sản phẩm chăm sóc da an toàn, không dùng thuốc.\n- **NCT02404493** là thử nghiệm về kem dưỡng ẩm OTC cho trẻ nhỏ (6-47 tháng), thời gian ngắn hơn (khoảng 3 tuần), phù hợp nếu bạn muốn thử kem dưỡng ẩm đơn giản, ít phức tạp hơn.\n\n### Gợi ý:\n- Nếu bạn muốn thử thuốc đặc trị và sẵn sàng tham gia dài hơn, NCT02094235 có thể phù hợp.\n- Nếu bạn chỉ muốn thử các sản phẩm chăm sóc da an toàn, không dùng thuốc mạnh, NCT03719742 hoặc NCT02404493 có thể phù hợp hơn, đặc biệt là NCT02404493 nếu bạn muốn thời gian ngắn hơn.\n\nNếu bạn cần giúp chọn thử nghiệm phù hợp hơn hoặc có câu hỏi khác, tôi sẵn sàng hỗ trợ!",
      "trial_data": [
        {
          "nct_id": "NCT02094235",
          "title": "A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria\r\n\r\n          1. Pediatric out-patients diagnosed with AD aged 2 to 15 years at the time of written\r\n             informed consent. Diagnosis for AD should be made in accordance with the \"Guidelines\r\n             for Management of Atopic Dermatitis\" by the Japanese Dermatological Association.\r\n\r\n          2. Mild to moderate clinical symptoms appearing at baseline in areas where the\r\n             application of study drug is possible, except the skin of face/head and non-dermal\r\n             areas such as mucosa\r\n\r\n          3. Evaluable skin lesions appearing at baseline. \"Evaluable skin lesion\" means rash area\r\n             of 25 to 100 cm2 in the trunk or extremities, in which at least one of dermal symptoms\r\n             (erythema, exudate/eschar, excoriation or lichenification) must be moderate in\r\n             severity.\r\n\r\n          4. Continuous use of an appropriate moisturizer for at least 14 days before baseline\r\n\r\n          5. Females of child-bearing potential must be negative for pregnancy test at baseline and\r\n             are able to practice effective contraception during the study period including the\r\n             follow-up period\r\n\r\n          6. Virile males and females of childbearing potential, who and whose partners consented\r\n             to practice contraception throughout the study period after receiving an explanation\r\n             using the informed consent form and the separately-prepared assent form\r\n\r\n          7. Patients whose legally acceptable representatives (caregivers) are able to consent in\r\n             writing to participate in the study and who are able to adhere to the protocol\r\n             requirements. For patients aged 12 years or older at the time of informed consent,\r\n             written consent should be obtained from the patients as well as their legally\r\n             acceptable representatives (caregivers). Also for patients aged below 12 years,\r\n             written informed consent should be obtained whenever possible.\r\n\r\n        Exclusion Criteria\r\n\r\n          1. Use of biological products which may affect the pathological evaluation of AD within 6\r\n             months before the start of study treatment\r\n\r\n          2. Concurrent or recent use of certain topical or systemic medications or phototherapy\r\n             without a sufficient washout period, except hydrocortisone butyrate preparations used\r\n             in areas which are unsuitable for application of study drug at the discretion of the\r\n             investigator\r\n\r\n          3. Currently has Kaposi's varicelliform eruption, scabies, molluscum contagiosum,\r\n             impetigo contagious, psoriasis, connective tissue disorder, or Netherton's syndrome,\r\n             etc, which may affect the pathological evaluation of AD\r\n\r\n          4. Any past history or present illness of serious allergy such as anaphylactic shock,\r\n             anaphylactic reaction and anaphylactoid reaction, or any past history or present\r\n             illness of drug allergic reaction or hypersensitivity\r\n\r\n          5. Has active infection that requires oral or intravenous administration of antibiotics,\r\n             antifungal or antivirus agents at baseline\r\n\r\n          6. Currently has an advanced disease or highly abnormal laboratory test result that may\r\n             affect the safety of subject or the implementation of the study\r\n\r\n          7. Difficulty in venous access for blood collection\r\n\r\n          8. Any past history or present illness of malignant tumor, lymphoma, leukemia or\r\n             lymphoproliferative disorder, except non-melanoma skin carcinoma (e.g., squamous cell\r\n             carcinoma and basal cell carcinoma) which was completely removed and has not recurred\r\n             or metastasized for at least 5 years\r\n\r\n          9. Scheduled for surgery during the study\r\n\r\n         10. Concurrently enrolled in another clinical study or used any investigational drug or\r\n             device within 30 days before the date of informed consent\r\n\r\n         11. Ineligible for participating in the study for other reasons, in the judgment of the\r\n             investigator or subinvestigator",
          "brief_summary": "This is a multicenter, double-blind, vehicle-control study of 0.05% and 0.2% E6005 ointment.\r\n      Pediatric subjects with atopic dermatitis (AD) will be grouped into two; an elder group\r\n      (childhood - adolescent: 7 to 15 years of age) and a younger group (children: 2 to 6 years of\r\n      age) according to the sequential cohorts by confirming the safety.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT03719742",
          "title": "A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          1. Healthy, female or male infants/children, aged 6 months through 7 years.\r\n\r\n          2. In generally good health (physical, mental, and social well-being, not merely the\r\n             absence of disease/infirmity), according to parent/legal guardian report.\r\n\r\n          3. Having Fitzpatrick skin type I-VI (refer to Appendix I: Fitzpatrick Skin Type).\r\n\r\n          4. Having mild to moderate eczema involving 3% to 20% of body surface area, and with EASI\r\n             score in the range of 1.1 to 20.0, further stratified into the following subgroups:\r\n\r\n               -  Approximately 60% of subjects with clinically determined EASI score of 1.1-7.0\r\n                  (mild)\r\n\r\n               -  Approximately 40% of subjects with clinically determined EASI score of 7.1 to\r\n                  20.0 (moderate)\r\n\r\n          5. Having a parent/legal guardian at least 18 years of age who regularly bathes the child\r\n             and otherwise cares for the child, and who presents proof of guardianship (eg,\r\n             insurance card, certificate of residence, or copy of officially issued family\r\n             registration) at the baseline visit.\r\n\r\n          6. Having a parent/legal guardian willing to provide written informed consent and who can\r\n             read, speak, write, and understand English.\r\n\r\n          7. Whose parent/legal guardian is willing to sign a photography release.\r\n\r\n          8. Willing, and having a parent/legal guardian who is willing, to cooperate and\r\n             participate by following study requirements (including those outlined in section 7.3)\r\n             for the duration of the study and to report any changes in health status or\r\n             medications, AE symptoms, or reactions immediately.\r\n\r\n          9. Willing to bring in currently used moisturizer and cleanser to visit 1 for\r\n             documentation by clinic staff.\r\n\r\n        Exclusion Criteria:\r\n\r\n          1. Diagnosed with known allergies to skin care products or ingredient(s) in the test\r\n             product.\r\n\r\n          2. History of skin cancer within the past 5 years.\r\n\r\n          3. Individuals who have clinically active bacterial, fungal, or viral skin infections or\r\n             those who have a history of recurrent cutaneous infections, according to subject\r\n             self-report.\r\n\r\n          4. Individuals whose use of topical corticosteroids or systemic medications for their\r\n             eczema has not been stable for at least 6 weeks prior to study start. This includes\r\n             medicines such as hydrocortisone, clobetasol, betamethasone, halobetasol, fluocinide,\r\n             diflorasone, mometasone, halcinonide, desoximetasone, pimecrolimus, tacrolimus,\r\n             crisabarole, and fluticasone.\r\n\r\n          5. Having a health condition and/or pre-existing or dormant dermatologic disease on the\r\n             body (eg, psoriasis, rosacea, acne [severe acne, acne conglobata, nodules, or cysts],\r\n             seborrheic dermatitis, severe excoriations.) that the Investigator or designee deems\r\n             inappropriate for participation or could interfere with the outcome of the study.\r\n\r\n          6. Who have observable suntan, scars, nevi, excessive hair, tattoos, or other dermal\r\n             conditions on the body that might influence the test results in the opinion of the\r\n             Investigator or designee.\r\n\r\n          7. Having a history of immunosuppression/immune deficiency disorders (including HIV\r\n             infection, AIDS, multiple sclerosis, Crohn's disease, rheumatoid arthritis), had an\r\n             organ transplant (heart, kidney, etc), or currently using oral or systemic\r\n             immunosuppressive medications and biologics that are not used for the treatment of\r\n             eczema (eg, azathioprine, belimumab, Cimzia, Cosentyx, cyclophosphamide, cyclosporine,\r\n             Enbrel, Humira, Imuran, Kineret, mycophenolate mofetil, methotrexate, Orencia,\r\n             Remicade, Rituxan, Siliq, Simponi, Stelara, Taltz) and/or undergoing radiation or\r\n             chemotherapy as determined by study documentation.\r\n\r\n          8. Having a disease such as asthma, diabetes, epilepsy, hypertension, hyperthyroidism, or\r\n             hypothyroidism that is not controlled by diet or medication; experiencing asthma\r\n             flares or having multiple health conditions.\r\n\r\n          9. Having started a long-term medication within the last 2 months.\r\n\r\n         10. With any planned surgeries and/or invasive medical procedures during the course of the\r\n             study. Non-invasive planned surgeries will be reviewed for their impact on the study\r\n             outcome and acceptability by the Investigator or designee.\r\n\r\n         11. Who are currently participating in any other clinical trial at Stephens, another\r\n             research facility, or doctor's office\r\n\r\n         12. Who have participated in any clinical trial or experimental treatment involving the\r\n             test area within 4 weeks prior to inclusion into the study at Stephens, at another\r\n             research facility or doctor's office.\r\n\r\n         13. Infants/children with a history of or exhibiting signs and symptoms of any systemic\r\n             disease that may interfere with study evaluations (eg, urinary tract infections,\r\n             significant bowel or urinary congenital malformation).\r\n\r\n         14. Infant/child who has had a recent change in her/his dietary intake or who has had\r\n             severe diaper rash within 1 week prior to baseline.\r\n\r\n         15. Individuals who have received PUVA therapy for atopic dermatitis within 4 weeks prior\r\n             to inclusion in the study.\r\n\r\n         16. Individuals who have received phototherapy within 2 weeks prior to inclusion in the\r\n             study.\r\n\r\n         17. Individuals who have changed the type of moisturizer or cleanser used within the last\r\n             6 weeks prior to inclusion in the study.",
          "brief_summary": "A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer\r\n      Under the Supervision of Dermatologist and Pediatrician",
          "detailed_description": "This single-center clinical trial is being conducted to demonstrate that the Sponsor's\r\n      product does not statistically or clinically worsen eczema scores in children aged 6 months\r\n      through 7 years after 4 weeks of treatment compared to baseline scores.\r\n\r\n      Safety and efficacy will be assessed through clinical grading at baseline and week 4.\r\n      Efficacy will also be assessed through Corneometer and Tewameter measurements at baseline and\r\n      week 4. Microbiome skin swab sampling will be performed at baseline and week 4.\r\n      Parents/guardians will complete Patient Oriented Eczema Measure and Family Dermatology\r\n      Quality of Life Index at baseline and week 4.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT02404493",
          "title": "Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          1. Able to comprehend and follow the requirements of the study (including availability on\r\n             scheduled visit dates)\r\n\r\n          2. Male or female of any race or ethnicity, 6 months to 47 months of age;\r\n\r\n          3. Diagnosed as having eczema\r\n\r\n          4. Willing to stop use of all non-assigned moisturizers and/or creams for the entire\r\n             duration of the study\r\n\r\n          5. Child must have bedtime/sleep issues due to their dry, itchy skin\r\n\r\n        Exclusion Criteria:\r\n\r\n          1. Use of a therapeutic (over-the-counter or prescription) body wash that contains an\r\n             active ingredient for eczema\r\n\r\n          2. Participation in any clinical study within 30 days of Visit 1\r\n\r\n          3. Active infection of any type at the start of the study\r\n\r\n          4. Diagnosed as having severe eczema\r\n\r\n          5. Atopic Dermatitis requiring systemic, super-potent (Class I) or potent (Class II or\r\n             III) topical corticosteroids\r\n\r\n          6. Child wakes up 3 or more times during the night\r\n\r\n          7. Child is awake more than 60 minutes during the night\r\n\r\n          8. Child sleeps for less than a total of 9 hours (during the day or night)\r\n\r\n          9. Child requires greater than 2.0 mg per day of inhaled or intranasal corticosteroids",
          "brief_summary": "The purpose of this 3 week study is to test the effectiveness of an over-the-counter (OTC)\r\n      skin balm in infants and toddlers with mild to moderate dry, itchy skin.",
          "detailed_description": "50 infants and toddlers will be enrolled in this study to yield 40 completed subjects, 30\r\n      babies in the active treatment group and 10 babies in the positive control group.\r\n\r\n      Infants and toddlers aged 6 to 47 months inclusive will receive either a prescription or\r\n      non-marketed investigational product for the treatment of eczema. Caregivers will be asked to\r\n      stop use of prescription eczema treatments one week before the start of the study and during\r\n      the study. Caregivers will apply study product to babies as indicated for 14 days to affected\r\n      areas.\r\n\r\n      Subject caregivers will record treatment use in a daily diary and complete questionnaires. A\r\n      dermatologist will examine and score the babies eczema and symptoms. Skin moisture levels\r\n      will also be tested.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 11.782721,
      "language": "vi",
      "llm_scores": {
        "hallucination": 3,
        "hallucination_reasoning": "Several details are not supported by the provided trial texts: (1) NCT02094235 is explicitly Phase 1/2, not just N/A/unknown; (2) NCT03719742 is described as single-center and 4 weeks, plus specific visit schedule, none of which are given; (3) NCT02404493 is stated to have baseline and week‑4 visits and 3‑week duration, but the protocol only mentions a 3‑week study and baseline, not week‑4; (4) Multiple assumptions about visit frequency, study duration, and current status (\"đang diễn ra hoặc chưa rõ\") are not grounded. These are embellishments rather than directly supported facts.",
        "accuracy": 3,
        "accuracy_reasoning": "Core concepts (all are pediatric/infant eczema/AD‑related, one is a drug, the others are cleanser/moisturizer) are broadly correct, and the age ranges and general inclusion ideas are mostly aligned. However, there are notable inaccuracies: mislabeling the phase of NCT02094235, inventing single‑center design and precise 4‑week schedule for NCT03719742, adding a week‑4 visit for NCT02404493, implying special 6‑week washout for NCT02404493 that actually belongs to NCT03719742, and speculative statements about study duration and status. Key eligibility nuances (e.g., sleep criteria in NCT02404493, English‑literate guardian in NCT03719742) are oversimplified.",
        "clarity": 4,
        "clarity_reasoning": "The table format is clear, structured, and easy for a lay reader to compare. Key ideas (type of intervention, age ranges, general demands) are communicated in a patient‑friendly way and the short recommendations at the end help with understanding which trial might be more or less demanding. Some cells are vague or contain speculative info about visits and duration, which slightly reduces clarity but overall the presentation is understandable and organized.",
        "language_correction": 5,
        "language_correction_reasoning": "User wrote in Vietnamese and the response is fully in Vietnamese, with consistent terminology and style. No language mismatch or unnecessary mixing with other languages beyond technical trial IDs."
      }
    },
    {
      "topic_number": "16",
      "trial_ids": [
        "NCT01074554",
        "NCT03926832"
      ],
      "query": "So sánh các thử nghiệm này: NCT01074554, NCT03926832",
      "response": "Claro, aquí tienes una comparación clara y sencilla de los dos ensayos clínicos NCT01074554 y NCT03926832, para ayudarte a entender las diferencias y decidir cuál puede ser más adecuado para ti.\n\n| **Aspecto**                     | **NCT01074554: Tratamiento antimicobacteriano en sarcoidosis** | **NCT03926832: Prevalencia de apnea del sueño en sarcoidosis y efecto del CPAP** |\n|---------------------------------|--------------------------------------------------------------|-------------------------------------------------------------------------------|\n| **Fase del estudio**            | No especificada (N/A)                                         | No especificada (N/A)                                                         |\n| **Tipo de tratamiento/intervención** | Uso de medicamentos antimicobacterianos para tratar sarcoidosis | Evaluación de la apnea del sueño y uso de CPAP para mejorar la fatiga        |\n| **¿Dónde se realiza?**          | No especificado (probablemente en centros especializados)   | No especificado (probablemente en hospitales o clínicas)                   |\n| **Frecuencia de visitas**         | No detallada, pero generalmente requiere visitas para seguimiento y análisis | No especificada, pero generalmente incluye visitas para evaluación y ajuste del CPAP |\n| **¿Quién puede participar?**     | - Adultos con sarcoidosis crónica, con lesiones cutáneas y sin infecciones activas<br>- Sin antecedentes de tuberculosis reciente<br>- Sin alergias a ciertos medicamentos<br>- Sin problemas de visión o antecedentes de síndrome de QT largo | - Personas con diagnóstico confirmado de sarcoidosis<br>- Sin tratamiento actual con CPAP<br>- Sin trastornos psiquiátricos |\n| **¿Cuánto dura el estudio?**     | No especificado (probablemente varias semanas a meses)       | No especificado, pero generalmente los estudios de apnea del sueño duran varias semanas a meses | \n| **Estado actual**                 | No especificado (probablemente en fase de reclutamiento o en curso) | No especificado (probablemente en curso o en análisis)                     |\n| **¿Qué lo hace diferente?**       | Se centra en tratar la sarcoidosis con medicamentos antimicobacterianos | Se enfoca en detectar y tratar la apnea del sueño en pacientes con sarcoidosis y evaluar cómo mejora la fatiga con CPAP |\n| **¿Qué implica para ti?**         | Requiere tomar medicamentos específicos y asistir a visitas para evaluar la respuesta | Requiere usar una máquina de CPAP para dormir y asistir a evaluaciones relacionadas con el sueño y la fatiga |\n| **¿Qué debes considerar?**        | Es un tratamiento activo que puede tener efectos secundarios por medicamentos | Es un estudio que puede requerir usar una máquina durante la noche, pero no implica medicamentos |\n\n**Resumen para ti:**\n- Si buscas un tratamiento que pueda mejorar la sarcoidosis con medicamentos antimicobacterianos, el primer estudio (NCT01074554) sería el indicado. Sin embargo, puede requerir más visitas y seguimiento con medicamentos.\n- Si te preocupa la fatiga y sospechas que puede deberse a apnea del sueño, el segundo estudio (NCT03926832) puede ser más adecuado, ya que se centra en detectar y tratar la apnea con una máquina de CPAP, lo cual puede ser menos invasivo y más enfocado en mejorar la calidad del sueño y la energía.\n\n¿Quieres más detalles sobre alguno de estos estudios o ayuda para decidir cuál puede ser mejor para ti?",
      "trial_data": [
        {
          "nct_id": "NCT01074554",
          "title": "Trial of Antimycobacterial Therapy in Sarcoidosis",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as\r\n             defined by the clinical presentation consistent with sarcoidosis, biopsy finding\r\n             granulomas, and no alternative for the cause of the granulomas, such as tuberculosis\r\n\r\n          2. Patients must have chronic cutaneous skin lesions with or without taking chronic\r\n             therapy (corticosteroids, methotrexate (max 10mg/week), azathioprine,\r\n             hydroxychloroquine, cyclophosphamide, minocycline, doxycycline and chloroquine), in\r\n             which the dose has not been altered in the 2 months prior to starting the study.\r\n\r\n          3. Subject has a diagnosis of cutaneous sarcoidosis for greater than 6 months with a\r\n             Sarcoidosis Activity and Severity Index assessment score of at least 4. Diagnosis can\r\n             be made by either:\r\n\r\n               -  Skin lesions characteristic of sarcoidosis and a biopsy showing granulomas with\r\n                  no evidence of mycobacteria, fungus, or malignancy.\r\n\r\n               -  A biopsy that does not show granulomas, but the patient has characteristic skin\r\n                  lesions and history of clinical features suggesting sarcoidosis (previous biopsy\r\n                  revealing noncaseating granuloma, bilateral hilar adenopathy, erythema nodosum,\r\n                  uveitis, raised ACE level, BAL lymphocytosis (CD4:CD8>3.5), panda/lambda sign on\r\n                  gallium scan)\r\n\r\n               -  Accepted clinical variants include, but are not necessarily limited to the\r\n                  following:\r\n\r\n                    -  lupus pernio\r\n\r\n                    -  nodular\r\n\r\n                    -  subcutaneous\r\n\r\n                    -  annular\r\n\r\n                    -  angiolupoid\r\n\r\n                    -  plaque\r\n\r\n                    -  papular\r\n\r\n                    -  lichenoid\r\n\r\n                    -  psoriasiform\r\n\r\n               -  For purposes of this study \"moderate to severe cutaneous sarcoidosis\" is defined\r\n                  as the presence of sarcoidal skin lesions with any of the following features:\r\n\r\n                    -  At least 5 easily visible facial lesions, or\r\n\r\n                    -  Disease which involves > 3% BSA, or\r\n\r\n                    -  Disease which confers functional impairment (e.g. nasal or visual field\r\n                       obstruction), or\r\n\r\n                    -  Disease which confers significant symptoms of itching and/or pain.\r\n\r\n          4. If female, subject is either not of childbearing potential, defined as postmenopausal\r\n             for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral\r\n             oophorectomy, or hysterectomy), or is using one of the following methods of birth\r\n             control for the duration of the study and 90 days after study completion:\r\n\r\n               -  condoms, sponge, foams, jellies, diaphragm, or intrauterine device\r\n\r\n               -  contraceptives (oral or parenteral) for three months prior to study drug\r\n                  administration\r\n\r\n               -  a vasectomized sole partner\r\n\r\n               -  Females of childbearing potential must have a negative serum pregnancy test at\r\n                  screening visit.\r\n\r\n        Exclusion Criteria:\r\n\r\n          1. No consent/inability to obtain consent.\r\n\r\n          2. Age less than 18 years of age.\r\n\r\n          3. Inability to obtain biopsy or draw blood.\r\n\r\n          4. CPK, ALT or AST >5 times upper limit of normal (ULN)\r\n\r\n          5. Pregnancy or breast feeding.\r\n\r\n          6. Current use of medications metabolized by rifampin (See Appendix).\r\n\r\n          7. Allergy to macrolides, quinolones or rifamycins.\r\n\r\n          8. Visual Impairment as defined by differentiating colors.\r\n\r\n          9. Family or personal history of long QT syndromes.\r\n\r\n         10. Patients receiving another interventional investigational drug within the 30 days\r\n             prior to dosing\r\n\r\n         11. Use of any investigational medication within the past 28 days prior to study\r\n             enrollment.\r\n\r\n         12. Subject has been hospitalized for infection or received IV antibiotics within the\r\n             previous 2 months prior to baseline.\r\n\r\n         13. Subject has a history of tuberculosis at anytime or close contact with a person with\r\n             active tuberculosis within the previous 6 months, or persistent or active infections\r\n             requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV\r\n             antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or\r\n             antifungals for purpose of treating infection, within 14 days of baseline.\r\n\r\n         14. Evidence of other active skin diseases or skin infections during screening that may\r\n             interfere with evaluation of sarcoidosis.\r\n\r\n         15. Subject has an active infection requiring systemic antibiotics at time of screening\r\n\r\n         16. Subject has a history of listeriosis, treated or untreated tuberculosis, exposure to\r\n             individuals with tuberculosis.\r\n\r\n         17. Subject has a variant of sarcoidosis that is not amenable to study evaluation, in the\r\n             absence of chronic indurated lesions, such as:\r\n\r\n               -  Acute, \"benign\" sarcoid associated with erythema nodosum\r\n\r\n               -  Acute iritis\r\n\r\n               -  Ichthyosiform sarcoidosis\r\n\r\n               -  Hypo- or hyperpigmented macular sarcoidosis\r\n\r\n               -  Ulcerative sarcoidosis\r\n\r\n               -  Erythroderma\r\n\r\n               -  Alopecia\r\n\r\n         18. Patients otherwise unsuitable for participation in the opinion of the investigator",
          "brief_summary": "Growing research from independent laboratories provide an association between mycobacteria\r\n      and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses\r\n      to mycobacteria virulence factors. The purpose of this study is to assess if administration\r\n      of anti-mycobacterial drug therapy will aid in resolution of cutaneous sarcoidosis lesions.",
          "detailed_description": "Independent molecular and immunologic investigations strengthen the association between\r\n      mycobacterial antigens and sarcoidosis pathogenesis. Molecular analysis of sarcoidosis\r\n      granulomas reveals the presence of Mycobacterium tuberculosis complex (MTB) DNA and proteins\r\n      that are significantly absent from granulomatous controls. Mycobacterial DNA has been\r\n      detected in cutaneous sarcoidosis lesions, in addition to systemic immune responses against\r\n      mycobacterial antigens. Due to the association between sarcoidosis and mycobacterial\r\n      antigens, we postulated that broad spectrum antimycobacterial therapy could lead to\r\n      restoration of T cell function and clinical improvement of chronic cutaneous sarcoidosis\r\n      lesions. We investigated the safety and efficacy of Concomitant Levofloxacin, Ethambutol,\r\n      Azithromycin, and Rifampin (CLEAR) therapy among chronic cutaneous sarcoidosis subjects, with\r\n      change in lesion diameter from baseline to completion of 8 weeks of therapy as the primary\r\n      endpoint; we assessed for decreases in granuloma burden, if granulomas were evident upon\r\n      histologic examination. Change in modified Sarcoidosis Activity Severity Index (SASI) was the\r\n      secondary endpoint.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT03926832",
          "title": "Prevalence of Obstructive Sleep Apnea Syndrome in Sarcoidosis and Impact of CPAP Treatment on Associated Fatigue Status",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Subjects with a definite diagnosis of sarcoidosis according to international ATS and\r\n             WASOG guideline\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Ongoing CPAP treatment\r\n\r\n          -  Psychiatric disorders",
          "brief_summary": "Sarcoidosis is a multisystemic granulomatous disease that affects individuals worldwide\r\n      without known pathogenesis, and the role of comorbidities has not been fully assessed in the\r\n      scientific literature. An increased incidence of Obstructive Sleep Apnea Syndrome (OSAS) has\r\n      been described in Sarcoidosis although this association has not been explained yet and no\r\n      data is available about the effect of treatment with Continuous Positive Airway Pressure\r\n      (CPAP) in Sarcoidosis. Also, patients affected by Sarcoidosis usually experience a state of\r\n      physical and mental weariness called fatigue and reported in approximately 60-80% sarcoid\r\n      patients and thought to be a consequence of inflammatory mediators but the high prevalence of\r\n      OSAS could be a remarkable bias in clinical evaluation because fatigue is also strongly\r\n      associated with sleep disorders.\r\n\r\n      Thus, there is a real need for assessing not only the real prevalence of OSAS in Sarcoidosis\r\n      but also the effect of CPAP treatment on fatigue status experienced by sarcoidotic patients.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 8.218608,
      "language": "vi",
      "llm_scores": {
        "hallucination": 3,
        "hallucination_reasoning": "Several speculative elements not grounded in the trial text: assumes both are interventional treatment studies (CPAP as a treatment arm) when NCT03926832 is primarily prevalence/impact; infers likely status as \"in course\" or \"recruitment\"; infers visit frequency and duration for both trials; suggests NCT03926832 is \"less invasive\" and requires CPAP use for all, which is not stated. These are plausible but not supported by the provided descriptions.",
        "accuracy": 3,
        "accuracy_reasoning": "Core high-level contrast (drug therapy for cutaneous sarcoidosis vs. OSAS prevalence and CPAP impact on fatigue in sarcoidosis) is correct, and eligibility is summarized reasonably. However, there are multiple inaccuracies/overinterpretations: presents NCT03926832 as mainly a CPAP treatment study rather than a prevalence plus impact assessment; implies all participants will use CPAP; invents location, visit frequency, duration, and current status; does not clearly note that NCT01074554 is limited to chronic cutaneous sarcoidosis with specific severity and complex exclusions. Mix of correct and incorrect/assumed details.",
        "clarity": 5,
        "clarity_reasoning": "Very clear and patient-friendly, with a well-structured comparison table and a short summary explaining which trial might be more suitable depending on goals (treat sarcoidosis vs. address fatigue/apnea). It highlights key aspects (intervention type, who can participate, implications) in accessible language.",
        "language_correction": 4,
        "language_correction_reasoning": "User asked in Vietnamese, but the response is entirely in Spanish. It is consistent within itself but does not match the user’s language at all; according to the rubric this should be penalized (closer to a mismatch than a partial match)."
      }
    },
    {
      "topic_number": "15",
      "trial_ids": [
        "NCT01523964",
        "NCT00847379",
        "NCT01380964"
      ],
      "query": "So sánh các thử nghiệm này: NCT01523964, NCT00847379, NCT01380964",
      "response": "Dưới đây là so sánh rõ ràng giữa 3 thử nghiệm lâm sàng dựa trên thông tin bạn cung cấp:\n\n| **Tiêu chí**                     | **NCT01523964** (DART EIM in DMD & Healthy Controls) | **NCT00847379** (Ataluren in DMD/BMD) | **NCT01380964** (Biomarkers in DMD) |\n|----------------------------------|-----------------------------------------------------|-------------------------------------|----------------------------------|\n| **Giai đoạn**                   | Không xác định (N/A)                                | Không xác định (N/A)                | Không xác định (N/A)             |\n| **Loại điều trị**                | Đo lường bằng phương pháp không xâm lấn (Electrical Impedance Myography) | Thuốc thử (Ataluren) để giúp sửa lỗi di truyền | Nghiên cứu về dấu hiệu sinh học (biomarkers) để chẩn đoán và theo dõi bệnh |\n| **Yêu cầu về địa điểm**          | Không rõ, có thể tại các trung tâm nghiên cứu | Không rõ, đa quốc gia | Không rõ, có thể tại các trung tâm nghiên cứu |\n| **Tần suất khám**                 | Thăm khám trong các lượt khám ban đầu, không rõ tần suất cụ thể | Thăm khám định kỳ, theo lịch của nghiên cứu | Thăm khám để lấy mẫu máu, tần suất không rõ cụ thể |\n| **Điều kiện tham gia chính**      | - Trẻ nam từ 3-7 hoặc 8-12 tuổi, có DMD hoặc khỏe mạnh<br>- Có khả năng đi bộ 10m<br>- Không dùng thuốc ảnh hưởng đến cơ trong 4 tuần gần nhất | - Đã hoàn thành nghiên cứu trước đó<br>- Trẻ từ 4-18 tuổi, có DMD do đột biến nonsense<br>- Không dị ứng thuốc | - Trẻ nam từ trên 3 tuổi, có xác nhận DMD<br>- Không có bệnh lý khác ảnh hưởng đến cơ hoặc viêm nhiễm gần đây |\n| **Yêu cầu loại trừ**             | - Không có các bệnh lý khác ảnh hưởng đến cơ<br>- Không tham gia nghiên cứu khác gần đây | - Dị ứng thuốc<br>- Tham gia nghiên cứu khác<br>- Các bệnh lý ảnh hưởng đến an toàn hoặc kết quả | - Các bệnh lý khác ảnh hưởng đến cơ hoặc viêm nhiễm gần đây<br>- Sử dụng thuốc khác ngoài quy định |\n| **Thời gian tham gia**            | Không rõ, có thể dài vài tuần đến vài tháng | Thường dài vài tháng đến hơn 1 năm | Không rõ, chủ yếu lấy mẫu máu, có thể ngắn hơn |\n| **Tình trạng hiện tại**           | Không rõ | Không rõ | Không rõ |\n| **Điểm đặc biệt khác**            | Nghiên cứu về phương pháp đo không xâm lấn, phù hợp cho trẻ nhỏ | Nghiên cứu về thuốc mới giúp sửa lỗi di truyền, phù hợp cho trẻ đã từng tham gia nghiên cứu trước | Nghiên cứu về dấu hiệu sinh học, phù hợp để theo dõi tiến trình bệnh |\n\n### So sánh tổng quát:\n- **NCT01523964** tập trung vào phương pháp đo không xâm lấn để đánh giá cơ, phù hợp nếu bạn muốn tránh các thủ thuật xâm lấn như chọc kim.\n- **NCT00847379** là nghiên cứu về thuốc Ataluren, dành cho trẻ đã hoàn thành nghiên cứu trước, có thể kéo dài hơn và yêu cầu theo dõi thuốc.\n- **NCT01380964** là nghiên cứu về các dấu hiệu sinh học, có thể phù hợp nếu bạn quan tâm đến việc theo dõi bệnh qua các xét nghiệm máu.\n\n### Lời khuyên:\n- Nếu bạn muốn tham gia một nghiên cứu không xâm lấn, NCT01523964 có thể phù hợp.\n- Nếu con bạn đã từng tham gia nghiên cứu thuốc hoặc bạn quan tâm đến thuốc mới, NCT00847379 là lựa chọn.\n- Nếu bạn quan tâm đến việc xác định các dấu hiệu sinh học để theo dõi bệnh, NCT01380964 phù hợp hơn.\n\nNếu bạn cần biết thêm về yêu cầu thời gian, địa điểm hoặc mức độ khó khăn của từng thử nghiệm, tôi sẵn sàng giúp đỡ!",
      "trial_data": [
        {
          "nct_id": "NCT01523964",
          "title": "DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n        DMD Subject Cohorts\r\n\r\n          -  Male subjects\r\n\r\n          -  Subjects with a chronologic age of 3 to 7 years inclusive for Cohort A, and 8 to 12\r\n             years inclusive for Cohort B\r\n\r\n          -  Subjects with DMD diagnosed with mutational testing and/or absence of dystrophin on\r\n             muscle biopsy\r\n\r\n          -  Subjects with proximal pelvic girdle weakness (Gower's maneuver, difficulty with\r\n             arising from floor and going up steps)\r\n\r\n          -  Subjects who can walk 10 meters unassisted (ie, without braces, canes, or other aids)\r\n\r\n          -  Subjects who are taking systemic corticosteroids and/or any other medication which, in\r\n             the judgment of the investigator, could impact muscle strength or physical activity\r\n             levels, must be on a stable dose for at least 4 weeks prior to initiation of study\r\n             measurements\r\n\r\n          -  Subjects who provide assent, as stipulated by IRB requirements, and whose\r\n             parent/guardian signs an informed consent form\r\n\r\n          -  Subjects who are willing and able to cooperate and comply with all protocol\r\n             requirements and procedures\r\n\r\n        Healthy Control Cohort\r\n\r\n          -  Healthy males with normal neuromuscular examination\r\n\r\n          -  Subjects with a chronologic age of 3 to 7 years inclusive for Cohort C, and 8 to 12\r\n             years inclusive for Cohort D\r\n\r\n          -  Subjects who provide assent, as stipulated by IRB requirements, and whose\r\n             parent/guardian signs an informed consent form\r\n\r\n          -  Subjects who are willing and able to cooperate and comply with all protocol\r\n             requirements and procedures\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Subjects with daytime ventilatory dependence (non-invasive or tracheostomy)\r\n\r\n          -  Subjects enrolled in a DMD therapeutic clinical trial concomitantly or within the past\r\n             4 weeks\r\n\r\n          -  Subjects with any physical or mental condition which may, in the investigator's\r\n             opinion, render the subject unable to complete the tasks of the study appropriately",
          "brief_summary": "Physicians seek a method to assess neuromuscular disease that is both non-invasive and\r\n      quantifiable. Many patients do not tolerate standard current day assessment tools (such as\r\n      needle electromyogram), and Electrical Impedance Myography (EIM) has the potential to serve\r\n      as a non-invasive, quantifiable, diagnostic tool for neuromuscular disease. If successful,\r\n      these devices will allow for improved ability to diagnose neuromuscular disease and to assess\r\n      disease progression or remission, allowing for better care of individual patients as well as\r\n      for use in clinical trials, where improved outcome measures for neuromuscular diseases is\r\n      being sought.",
          "detailed_description": "Healthy subjects and subjects with DMD will be screened during Visit 1. Screening evaluations\r\n      will establish eligibility and will include a medical history, abbreviated physical\r\n      examination, vital signs (blood pressure, temperature, pulse, and respirations), and weight.\r\n      Eligible subjects will provide assent, as stipulated by Institutional Review Board (IRB)\r\n      requirements, and a parent/guardian will sign an informed consent, after which the subject\r\n      will be considered enrolled.\r\n\r\n      Subjects will be enrolled into 4 study cohorts for a total of approximately 90 subjects.\r\n      Allocation into these cohorts is planned due to considerations regarding the effect of age on\r\n      outcomes.\r\n\r\n      Visit 2, Study Assessments, may take place on the day of Visit 1 screening evaluations. If\r\n      the subject cannot complete study assessments on the same day, the subject may return and\r\n      complete Visit 2 evaluations within approximately 24 hours of the end of Visit 1.\r\n\r\n      Visit 2 assessments will include morphological testing of muscle length and girth, skin fat\r\n      measurement, Clinical Assessments (6-Minute Walk Test [6MWT], North Star Ambulatory\r\n      Assessment, timed function tests, dynamometry), and 3 phases of Device Performance testing.\r\n      Phase 1 Device Performance testing will be done by each of 2 trained raters (Rater A and\r\n      Rater B) from the research site, designated to perform the Device Performance testing on all\r\n      subjects at their respective site. At least 10 minutes after completion of the first\r\n      assessments, Phase 2 Device Performance testing will be repeated by Rater A. Upon completion\r\n      of the Phase 2 Device Performance testing, the subjects will proceed with Clinical\r\n      Assessments performed by a physical therapist. Following Clinical Assessments, Phase 3 Device\r\n      Performance testing will be performed by Rater B.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT00847379",
          "title": "Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Completion of blinded study drug treatment in the previous Phase 2b study\r\n             (PTC124-GD-007-DMD).\r\n\r\n          -  Ability to provide written informed consent (parental/guardian consent if\r\n             applicable)/assent (if less than [<]18 years of age).\r\n\r\n          -  In participants who are sexually active, willingness to abstain from sexual\r\n             intercourse or employ a barrier or medical method of contraception during PTC124\r\n             administration and the 6-week follow up period.\r\n\r\n          -  Willingness and ability to comply with scheduled visits, drug administration plan,\r\n             study procedures, laboratory tests, and study restrictions.\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Known hypersensitivity to any of the ingredients or excipients of the study drug\r\n             (Litesse® UltraTM [refined polydextrose], polyethylene glycol 3350, Lutrol® micro F127\r\n             [poloxamer 407], mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla,\r\n             Cab-O-Sil® M5P [colloidal silica], magnesium stearate).\r\n\r\n          -  Ongoing participation in any other therapeutic clinical trial.\r\n\r\n          -  Prior or ongoing medical condition (for example, concomitant illness, psychiatric\r\n             condition, behavioral disorder, alcoholism, drug abuse), medical history, physical\r\n             findings, ECG findings, or laboratory abnormality that, in the investigator's opinion,\r\n             could adversely affect the safety of the subject, makes it unlikely that the course of\r\n             treatment or follow up would be completed, or could impair the assessment of study\r\n             results.",
          "brief_summary": "Duchenne/Becker muscular dystrophy (DMD/BMD) is a genetic disorder that develops in boys. It\r\n      is caused by a mutation in the gene for dystrophin, a protein that is important for\r\n      maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility\r\n      that leads to weakness and loss of walking ability during childhood and teenage years. A\r\n      specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of\r\n      DMD/BMD in approximately 10-15% of boys with the disease. Ataluren (PTC124) is an orally\r\n      delivered, investigational drug that has the potential to overcome the effects of the\r\n      nonsense mutation. This study is a Phase 2b extension trial that will evaluate the long-term\r\n      safety of ataluren (PTC124) in boys with nonsense mutation DMD/BMD, as determined by adverse\r\n      events and laboratory abnormalities. The study will also assess changes in walking, muscle\r\n      function, and other important clinical and laboratory measures.",
          "detailed_description": "This is a Phase 2b, international, multicenter, open-label extension study for participants\r\n      who successfully completed blinded study drug in Study 007. This extension study will\r\n      evaluate the long-term administration of ataluren administered 3 times per day (TID) at\r\n      morning, midday, and evening doses of 20, 20, and 40 milligrams/kilogram (mg/kg),\r\n      respectively, in participants with nonsense mutation Duchenne/Becker muscular dystrophy\r\n      (nmDBMD).",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT01380964",
          "title": "Research of Biomarkers in Duchenne Muscular Dystrophy Patients",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  FOR PATIENTS:\r\n\r\n          -  Diagnosis of DMD confirmed by genetic testing\r\n\r\n          -  Age over 3 years\r\n\r\n          -  Weight over 15 kg\r\n\r\n          -  Informed consent signed\r\n\r\n          -  FOR CONTROLS:\r\n\r\n          -  Age over 3 years\r\n\r\n          -  Male gender\r\n\r\n          -  Weight over 15 kg\r\n\r\n          -  Subjects with national health insurance coverage\r\n\r\n          -  Informed consent signed\r\n\r\n          -  Nonacute or chronic muscular, allergic, infectious, endocrine or inflammatory disorder\r\n             in the 3 weeks preceding inclusion\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  FOR PATIENTS:\r\n\r\n          -  Concomitant chronic or acute muscular, endocrine, infectious, allergic or inflammatory\r\n             disorder in the three weeks preceding the blood test\r\n\r\n          -  Intake of medicines other than angiotensin-converting enzyme inhibitors, beta\r\n             blockers, dietary supplements, vitamins, alendronate and methylphenidate. Steroids\r\n             (and medicines prescribed with them such as calcium supplements and proton pump\r\n             inhibitors) will be discussed\r\n\r\n          -  Mental retardation or autism\r\n\r\n          -  Vaccination or treatment with immunoglobulins within the three months preceding\r\n             inclusion\r\n\r\n          -  FOR CONTROLS:\r\n\r\n          -  Concomitant chronic or acute muscular, neurological (including mental retardation and\r\n             autism), infectious or inflammatory disorder in the three weeks preceding the blood\r\n             test\r\n\r\n          -  Vaccination or treatment with immunoglobulins within the three months preceding\r\n             inclusion",
          "brief_summary": "The purpose of this study is to identify potential biomarkers for the diagnosis, disease\r\n      progression assessment and response to treatment in patients with Duchenne Muscular\r\n      Dystrophy.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 7.819469,
      "language": "vi",
      "llm_scores": {
        "hallucination": 3,
        "hallucination_reasoning": "Several statements go beyond the provided data. Examples: NCT00847379 is labeled as including boys 4–18 years old (age range not given in the summary); NCT00847379 is called a multinational trial (no location info provided); visit frequency and overall study duration for all three trials are guessed; NCT01523964 is said to exclude anyone who used muscle‐affecting drugs in the last 4 weeks, whereas the text only requires a stable dose; some exclusion details are oversimplified. These are unsupported extrapolations, though the high‑level characterizations (EIM tool, Ataluren drug, biomarker study) are correct.",
        "accuracy": 3,
        "accuracy_reasoning": "Core distinctions are mostly correct (EIM measurement vs Ataluren drug vs biomarker research; inclusion of healthy controls vs only DMD/BMD; need to have completed prior Phase 2b trial for NCT00847379). However there are notable inaccuracies/omissions: age criteria are invented for NCT00847379; stability requirement for corticosteroids in NCT01523964 is misstated as a prohibition on recent use; exclusion criteria for each trial are compressed and partially misrepresented; location and duration are speculative. So it’s a mix of accurate high-level framing with several incorrect details.",
        "clarity": 5,
        "clarity_reasoning": "Very clear table format, Vietnamese patient-friendly language, and a concise narrative summary plus practical ‘which is suitable’ guidance. Key differences in purpose, burden, and invasiveness are highlighted in a way that would be easy for a patient/parent to understand.",
        "language_correction": 5,
        "language_correction_reasoning": "User wrote in Vietnamese and the comparison is entirely in Vietnamese, with only necessary trial identifiers and drug names in English. The language match is appropriate and consistent."
      }
    },
    {
      "topic_number": "9",
      "trial_ids": [
        "NCT00419796",
        "NCT00377208",
        "NCT03125733"
      ],
      "query": "So sánh các thử nghiệm này: NCT00419796, NCT00377208, NCT03125733",
      "response": "Dưới đây là so sánh rõ ràng giữa 3 thử nghiệm lâm sàng: NCT00419796, NCT00377208, và NCT03125733. Tôi đã trình bày theo dạng bảng để bạn dễ theo dõi các điểm chính:\n\n| Yếu tố                     | NCT00419796 (Hiệu quả của Lumiracoxib và Ibuprofen trên huyết áp và eicosanoids ở bệnh nhân thoái hóa khớp có huyết áp kiểm soát) | NCT00377208 (Chương trình web cá nhân để kiểm soát huyết áp) | NCT03125733 (Phẫu thuật nội soi điều trị Zenker's diverticulum) |\n|----------------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|\n| **Giai đoạn**             | Không rõ (không ghi rõ)                                                                                                         | Không rõ (không ghi rõ)                                       | Không rõ (không ghi rõ)                                       |\n| **Loại điều trị**          | So sánh thuốc NSAID (Lumiracoxib, Ibuprofen) và giả dược, ảnh hưởng đến huyết áp và eicosanoids                                | Chương trình web cá nhân cung cấp phản hồi cá nhân và khuyến khích giao tiếp với bác sĩ | Phẫu thuật nội soi tạo lỗ trong thực quản để điều trị Zenker's diverticulum |\n| **Yêu cầu địa điểm**       | Không yêu cầu đặc biệt, có thể tham gia tại các trung tâm nghiên cứu hoặc bệnh viện                                                     | Không yêu cầu, có thể tham gia từ nhà hoặc nơi làm việc (cần có internet) | Không yêu cầu, thực hiện tại bệnh viện hoặc trung tâm phẫu thuật |\n| **Tần suất khám**           | Không rõ, thường theo lịch của nghiên cứu (có thể vài lần trong quá trình)                                                        | Thường xuyên qua các cuộc trao đổi qua mạng, ít nhất 1 lần trong năm | Thường xuyên theo lịch hẹn sau phẫu thuật, có thể vài lần trong quá trình hồi phục |\n| **Điều kiện tham gia chính**| - Người lớn trên 50 tuổi, có thoái hóa khớp, huyết áp kiểm soát tốt, dùng thuốc huyết áp ổn định ít nhất 3 tháng | - Có tiền sử tăng huyết áp, đã được bác sĩ quản lý ít nhất 1 năm, có internet và email | - Chẩn đoán Zenker's diverticulum, có triệu chứng rõ ràng, sẵn sàng tham gia theo dõi |\n| **Điều kiện loại trừ**      | Dị ứng thuốc, bệnh ung thư, mang thai, bệnh tim mạch nặng, các phản ứng dị ứng với NSAID hoặc thuốc tương tự                     | Không thể nói và đọc tiếng Anh, mang thai, bị cản trở tâm thần, đang tham gia nghiên cứu khác | Không có triệu chứng tối thiểu, rối loạn đông máu, mang thai, bệnh nặng khác |\n| **Thời gian tham gia**      | Không rõ, có thể kéo dài vài tuần đến vài tháng (tùy theo thiết kế nghiên cứu)                                                    | Khoảng 1 năm hoặc lâu hơn, theo lịch trình của chương trình web | Thường từ vài tuần đến vài tháng, tùy theo quá trình hồi phục sau phẫu thuật |\n| **Tình trạng hiện tại**      | Không rõ (thông tin không cập nhật)                                                                                                | Không rõ (thông tin không cập nhật)                            | Không rõ (thông tin không cập nhật)                            |\n| **Điểm đặc biệt**           | So sánh thuốc ảnh hưởng huyết áp trong bệnh nhân thoái hóa khớp, phù hợp cho người đã kiểm soát huyết áp tốt                     | Tập trung vào tự quản lý huyết áp qua internet, phù hợp cho người có thể dùng máy tính | Phẫu thuật nội soi mới, ít xâm lấn, giúp điều trị Zenker's diverticulum hiệu quả hơn |\n\n### Điểm khác biệt chính:\n- **NCT00419796** tập trung vào thuốc và ảnh hưởng của chúng đến huyết áp và các chất liên quan trong bệnh nhân thoái hóa khớp, phù hợp nếu bạn đang dùng thuốc và muốn biết tác dụng phụ.\n- **NCT00377208** là chương trình trực tuyến giúp bạn kiểm soát huyết áp qua internet, phù hợp nếu bạn thích tự quản lý và có thể truy cập internet thường xuyên.\n- **NCT03125733** là phẫu thuật nội soi điều trị Zenker's diverticulum, phù hợp nếu bạn có triệu chứng của bệnh này và muốn điều trị bằng phương pháp ít xâm lấn hơn.\n\n### Gợi ý:\n- Nếu bạn quan tâm đến thuốc và huyết áp, NCT00419796 có thể phù hợp.\n- Nếu bạn muốn tự quản lý huyết áp qua mạng, NCT00377208 là lựa chọn tốt.\n- Nếu bạn bị Zenker's diverticulum và muốn điều trị bằng phẫu thuật nội soi, NCT03125733 là phù hợp.\n\nNếu bạn cần giúp chọn thử nghiệm phù hợp hơn hoặc muốn biết thêm chi tiết, hãy hỏi nhé!",
      "trial_data": [
        {
          "nct_id": "NCT00419796",
          "title": "Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Male and female outpatients of at least 50 years of age.\r\n\r\n          -  Female patients must be either post-menopausal for one year, surgically sterile, or\r\n             using effective contraceptive methods such as barrier method with spermicide or\r\n             intra-uterine device. Oral contraceptives use is not allowed 4 weeks prior screening\r\n             and throughout the duration of the study. Patients on hormonal replacement therapy are\r\n             allowed if they have been on a stable dose for at least 6 months.\r\n\r\n          -  Primary osteoarthritis of the hand, hip or knee according to American College of\r\n             Rheumatology (ACR) criteria or osteoarthritis of the spine. One joint will be\r\n             identified as the target joint and will be evaluated throughout the duration of the\r\n             trial.\r\n\r\n          -  Is expected to need non-steroidal anti-inflammatory drugs (NSAID) or simple analgesic\r\n             therapy for osteoarthritis for at least the next 6 weeks.\r\n\r\n          -  Controlled hypertension with mean sitting systolic blood pressure (MSSBP) <140 mmHg\r\n             and mean sitting diastolic blood pressure (MSDBP) <90 mmHg (mean of 3 cuff blood\r\n             pressure measurements). Patients must have taken the same fixed dose of\r\n             antihypertensive medication(s) on a regular basis for at least 3 consecutive months\r\n             prior to screening and are not expected to adjust their antihypertensive medication(s)\r\n             during the study. Regular wake-up times which are expected to continue for the\r\n             duration of the trial.\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  History of hypersensitivity to any of the study drugs or to drugs with similar\r\n             chemical structures.\r\n\r\n          -  Patients who have any known allergic-type reactions after taking acetylsalicylic acid\r\n             or NSAIDs which may include (but are not limited to) history of asthma, acute\r\n             rhinitis, nasal polyps, angioneurotic edema, urticaria or other allergic-type\r\n             reactions\r\n\r\n          -  History of malignancy of any organ system, treated or untreated, within the past 5\r\n             years whether or not there is evidence of local recurrence or metastases, with the\r\n             exception of localized basal cell carcinoma of the skin.\r\n\r\n          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a\r\n             female after conception and until the termination of gestation, confirmed by a\r\n             positive hCG laboratory test (> 5 mIU/ml).\r\n\r\n          -  History of cardiac and cerebral thrombotic/ ischemic diseases and/ or events as listed\r\n             below:\r\n\r\n        angina pectoris (of any severity) or other evidence of coronary heart disease; myocardial\r\n        infarction; coronary heart disease with ECG-evidence of silent myocardial infarction;\r\n        coronary artery bypass grafting (CABG) or percutaneous coronary intervention (any PCI\r\n        procedure); clinically significant carotid artery stenosis or history of carotid\r\n        endarterectomy; congestive heart failure, NYHA class II - IV; second or third degree heart\r\n        block in the absence of permanent pacing and all potentially life-threatening arrhythmia or\r\n        symptomatic arrhythmia; clinically significant valvular heart disease; cerebrovascular\r\n        disease; peripheral arterial disease\r\n\r\n        Other protocol-defined inclusion/exclusion criteria may apply",
          "brief_summary": "This randomized study will compare the effect of lumiracoxib, ibuprofen and placebo on\r\n      24-hour blood pressure profile and on urinary excretions of eicosanoids in controlled\r\n      hypertensive patients who have osteoarthritis.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT00377208",
          "title": "Individually Tailored Web-Based Program to Improve Blood Pressure Control",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  History of hypertension\r\n\r\n          -  At least one blood pressure value that is greater than recommended in the year prior\r\n             to study entry\r\n\r\n          -  An enrolled physician has provided care for managing the participant's blood pressure\r\n             for at least 1 year prior to study entry\r\n\r\n          -  Access to the internet at home or at work\r\n\r\n          -  Personal email account\r\n\r\n          -  At least one blood pressure value greater than 140/90 mm Hg (130/90 mm HG for diabetes\r\n             patients) in the one year prior to study entry\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Unable to speak and read English\r\n\r\n          -  Pregnant or plans to become pregnant in the year following study entry\r\n\r\n          -  Cognitively impaired\r\n\r\n          -  Currently incarcerated\r\n\r\n          -  Participating in another clinical research study\r\n\r\n          -  Planning on moving out of the area in the year following study entry",
          "brief_summary": "High blood pressure affects 65 million adults in the United States, and more than one third\r\n      of these individuals do not have adequate control of their blood pressure. Individuals who\r\n      ask specific questions and discuss important medical issues with their doctors are more\r\n      likely to receive appropriate medical care than individuals who do not. This study will\r\n      evaluate the effectiveness of an interactive web site that provides individualized feedback\r\n      and encourages doctor-patient communication as a way to maintain adequate blood pressure\r\n      control.",
          "detailed_description": "High blood pressure affects a third of the United States population; it is one of the most\r\n      common health problems in this country. With proper treatment, including weight loss, diet,\r\n      exercise, or medication, individuals can usually maintain adequate blood pressure control. A\r\n      large percentage of people, however, do not have their blood pressure under sufficient\r\n      control. Prompting individuals to ask their doctors specific medical questions has proven\r\n      effective in improving overall preventive medical care, but its effect on blood pressure\r\n      control among hypertensive individuals has not been evaluated. \"My Expert Doctor\" is a\r\n      web-based program that helps patients to ask the right questions regarding specific tests and\r\n      treatments during their doctor visits. Upon entering medication and treatment information\r\n      into the web site, patients are provided with individualized feedback and recommended\r\n      questions to ask their doctor. The purpose of this study is to evaluate the effectiveness of\r\n      the individualized, web-based intervention in improving blood pressure control in individuals\r\n      with high blood pressure.\r\n\r\n      Both physicians and their patients will be enrolled in this 1-year study. Participating\r\n      physicians will be randomly assigned to either the web-based intervention group or a control\r\n      group. Recruitment materials describing the study will be mailed to their patients who have\r\n      high blood pressure. Eligible patient participants will attend a baseline study visit, which\r\n      will include blood pressure measurements and self-report questionnaires. Patient participants\r\n      in the intervention group will receive access to the interactive section of the web site for\r\n      1 year. They will have the ability to enter their medication history, blood pressure\r\n      measurements, and blood test results. This information will then be analyzed against a\r\n      database containing the National Institutes of Health (NIH) blood pressure control\r\n      guidelines. Questions that participants may want to ask their physician, reasons for asking\r\n      the questions, and links to reputable web sites (e.g., American Heart Association) will then\r\n      be displayed. Automated email reminders will encourage participants to use the web site on a\r\n      monthly basis and prior to any doctor visits. Participants in the control group will be given\r\n      access to an area of the web site that does not provide individualized feedback, but does\r\n      contain information related to the prevention of high blood pressure. Baseline evaluations\r\n      will be repeated at a Year 1 study visit. Study researchers will review participants' medical\r\n      records to analyze serum creatinine test results and blood pressure measurements during the\r\n      1-year study and 1 year prior to the study.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT03125733",
          "title": "A New Treatment for Zenker's Diverticulum-submucosal Tunneling Endoscopic Septum Division",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Diagnosis of Zenker's diverticulum by symptoms, esophagram and/ or EGD\r\n\r\n          -  Symptomatic score≥2 in any of the symptoms or ≥3 in total\r\n\r\n          -  Patients or legal surrogates willing and competent to give informed consent and to\r\n             comply with follow up visits and tests\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Patients with minimal symptoms (score ≤1 in all four symptoms and <3 in total)\r\n\r\n          -  Presence of coagulopathy or pregnancy\r\n\r\n          -  Patients who, in the investigator's opinion, are medically unstable or have a life\r\n             expectancy of< 2 years, are unable to give informed consent or have poor compliance\r\n             with follow-up, or whose risks of participating in the study outweigh the benefits",
          "brief_summary": "Zenker's Diverticulum (ZD) is a sac-like outpouching of the lining of the esophageal wall at\r\n      the upper esophagus. It is a rare disease typically seen in the middle-aged and older adults.\r\n      Common symptoms of the disease include difficulties in swallowing (dysphagia), food reflux\r\n      (regurgitation), unpleasant breath smells (halitosis) and couch, choking and hoarseness etc.\r\n      (respiratory complications). Pills lodging in the sac and thus unable to take effect is also\r\n      a common and yet often overlooked problem.\r\n\r\n      Traditional treatment for ZD included open resection done by head and neck surgeons and\r\n      direct septum division done by ENT doctors. Septum division done by endoscopists is a new\r\n      modality of treatment and so far has used the same approach as the ENT doctors-the wall\r\n      between the sac and the normal esophageal lumen (the septum) is cut down directly so that\r\n      food will not be held in the sac.\r\n\r\n      A cutting-edge endoscopic treatment for ZD is now emerging. In this approach, what we call\r\n      submucosal tunneling endoscopic septum division (STESD), the wall is not cut directly, but\r\n      inside a tunnel created by lifting the wallpaper (the mucosa lining the esophageal wall).\r\n      After the muscle septum is completely cut, the mucosa is then sealed by clips, restoring\r\n      integrity of the esophageal lining.\r\n\r\n      The advantage of STESD is twofold. First, the esophageal mucosa will be sealed after the\r\n      operation, so that the chance of extravasation of luminal content with its relevant\r\n      complications will be smaller. Second, under the protection of the tunnel, the endoscopist\r\n      will be able to cut the septum completely down to its bottom, ensuring a more satisfactory\r\n      symptom resolution. In short, our hypothesis is that treating Zenker's diverticulum by the\r\n      tunneling endoscopic technique should be both safer and more effective than traditional\r\n      methods.",
          "detailed_description": "Patients with symptomatic Zenker's diverticulum are considered for STESD. The diagnosis is\r\n      based on clinical presentation, barium swallow, EGD and a swallow test to rule out other\r\n      possible disorders causing cervical dysphagia. A scoring system (Costamagna, GIE, 2016) is\r\n      used to evaluate severity of the symptoms. Four symptoms are evaluated: 1) dysphagia, 2)\r\n      regurgitation, 3) daytime respiratory symptoms and 4) nighttime respiratory symptoms. These\r\n      are scored based on a solid food diet according to the symptom frequency calculated within 2\r\n      consecutive weeks: 0-never, 1-1day/ week, 2-2~4days/ week, 3-≥5 days/ week. Under EGD and\r\n      barium swallow test, configuration of the diverticulum is documented in detail (Shou-Jiang\r\n      Tang, Laryngoscope, 2008). Quality of life is assessed using the SF-36 form. The pre- and\r\n      post-STESD symptom score, quality of life score, and diverticulum configuration are compared.\r\n\r\n      Adverse events are recorded and graded according to the system suggested by the ASGE workshop\r\n      (Cotton, GIE, 2010).",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 12.659618,
      "language": "vi",
      "llm_scores": {
        "hallucination": 3,
        "hallucination_reasoning": "Several details are speculative or not grounded in the provided records. Examples: (1) Visit frequency and duration for all 3 trials are guessed (“vài lần”, “khoảng 1 năm hoặc lâu hơn”, “vài tuần đến vài tháng”)—none of this is in the summaries. (2) “Có thể tham gia từ nhà hoặc nơi làm việc” for NCT00377208 is plausible but not stated. (3) “Không yêu cầu địa điểm, thực hiện tại bệnh viện hoặc trung tâm phẫu thuật” for NCT03125733 is generic but still not grounded in the text. (4) Claim that NCT00419796 is “phù hợp nếu bạn đang dùng thuốc và muốn biết tác dụng phụ” and that NCT03125733 is “ít xâm lấn, giúp điều trị ... hiệu quả hơn” extrapolates beyond the provided information and outcomes. These are modest but repeated embellishments, so not just “very minor”.",
        "accuracy": 3,
        "accuracy_reasoning": "Core characterization of each trial is mostly correct: NCT00419796 is a drug comparison in osteoarthritis with controlled hypertension; NCT00377208 is a web-based BP control program; NCT03125733 is an endoscopic treatment for Zenker’s diverticulum. Inclusion/exclusion summaries are broadly accurate. However, there are multiple inaccuracies/overinterpretations: (1) Phases labeled as “Không rõ (không ghi rõ)” while they are clearly listed as N/A. (2) Visit frequency and total participation time are invented. (3) Location/setting requirements are oversimplified or assumed. (4) For NCT03125733, calling it “phẫu thuật nội soi tạo lỗ trong thực quản” is a bit misleading versus the described submucosal tunneling with mucosal closure, and stating it is more effective than traditional methods is only hypothesized, not a demonstrated result. Thus, it’s a mix of accurate main points with several speculative details.",
        "clarity": 4,
        "clarity_reasoning": "The comparison is structured in a clear table with key rows (treatment type, eligibility, exclusions, visit frequency, time, etc.) and then a short summary plus suggestions about who each trial might suit. This is understandable and patient-friendly. Some rows (e.g., visit frequency, duration) mix guesses with facts, which could mislead patients, but the presentation itself is organized and easy to follow. Overall clarity is good, but the speculative content slightly undermines its usefulness for decision-making.",
        "language_correction": 5,
        "language_correction_reasoning": "User wrote in Vietnamese (“So sánh các thử nghiệm này...”), and the response is entirely in Vietnamese, with appropriate medical terminology and consistent language use. No noticeable mixing with other languages beyond necessary trial IDs and acronyms."
      }
    },
    {
      "topic_number": "7",
      "trial_ids": [
        "NCT02380729",
        "NCT04184817"
      ],
      "query": "So sánh các thử nghiệm này: NCT02380729, NCT04184817",
      "response": "Dưới đây là so sánh rõ ràng giữa hai thử nghiệm lâm sàng NCT02380729 và NCT04184817, giúp bạn dễ dàng hiểu các điểm khác biệt và giống nhau để đưa ra quyết định phù hợp:\n\n| **Tiêu chí**                     | **NCT02380729: Nghiên cứu về Đột biến trong Rối loạn Di truyền Không Mua lại** | **NCT04184817: Phân tích Hình ảnh về Bệnh Achondroplasia**             |\n|----------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------|\n| **Giai đoạn**                   | Không xác định (N/A)                                                            | Không xác định (N/A)                                                   |\n| **Loại điều trị / Nghiên cứu** | Phân tích gen (gene panel hoặc toàn bộ gen) để chẩn đoán và ảnh hưởng đến chi phí và chất lượng cuộc sống | Phân tích hình ảnh (chụp X-quang, MRI) để đánh giá mức độ hẹp ống sống | \n| **Địa điểm thực hiện**           | Bệnh viện tại Berlin, Đức (Charité-Universitätsmedizin Berlin)                | Bệnh viện tại Pháp (Hospital Femme Mère Enfant)                        |\n| **Yêu cầu đi lại**               | Không yêu cầu đi lại đặc biệt, chỉ lấy mẫu máu tại chỗ                            | Không yêu cầu đi lại, chỉ phân tích dữ liệu hình ảnh đã có             |\n| **Thời gian tham gia**            | Không rõ ràng, dự kiến sẽ liên quan đến xét nghiệm máu và theo dõi lâm sàng | Thường là phân tích dữ liệu đã có, không yêu cầu theo dõi dài hạn     |\n| **Tần suất khám**                 | Không xác định rõ, chủ yếu lấy mẫu máu và thu thập thông tin lâm sàng        | Không yêu cầu khám lặp lại, chỉ phân tích dữ liệu hình ảnh đã có       |\n| **Đối tượng tham gia**             | Trẻ em từ sơ sinh đến 18 tuổi, có nghi ngờ bệnh di truyền, cả nam và nữ        | Trẻ em từ 0 đến 18 tuổi đã chẩn đoán mắc Achondroplasia               |\n| **Tiêu chí loại trừ**             | Phản ứng với bệnh do nguyên nhân khác, không có sự đồng ý của cha mẹ hoặc người giám hộ | Không có phản đối sử dụng dữ liệu hoặc hình ảnh của bệnh nhân        |\n| **Mục tiêu chính**                | Cải thiện chẩn đoán, giảm chi phí y tế, nâng cao chất lượng cuộc sống        | Đánh giá mức độ hẹp ống sống và khả năng chịu đựng của bệnh nhân     |\n| **Tình trạng hiện tại**           | Không rõ (thông tin về trạng thái tuyển dụng hoặc hoàn thành không có)       | Không rõ, có thể đã thu thập dữ liệu hoặc đang trong quá trình phân tích |\n\n### Điểm khác biệt chính:\n- **Loại nghiên cứu**: Một bên tập trung vào phân tích gen để chẩn đoán và tác động kinh tế, bên kia tập trung vào phân tích hình ảnh để đánh giá mức độ hẹp ống sống trong bệnh Achondroplasia.\n- **Yêu cầu đi lại và thời gian**: NCT02380729 có thể yêu cầu lấy mẫu máu và theo dõi lâm sàng, trong khi NCT04184817 chủ yếu dựa trên dữ liệu hình ảnh đã có, không cần đi lại nhiều.\n- **Đối tượng tham gia**: Cả hai đều dành cho trẻ em từ sơ sinh đến 18 tuổi, nhưng mục đích và phương pháp khác nhau rõ rệt.\n\n### Gợi ý:\n- Nếu bạn quan tâm đến việc chẩn đoán chính xác và giảm chi phí y tế, thử nghiệm NCT02380729 có thể phù hợp hơn.\n- Nếu bạn muốn biết về mức độ hẹp ống sống của con bạn qua hình ảnh, thử nghiệm NCT04184817 có thể phù hợp hơn và ít yêu cầu đi lại.\n\nHy vọng bảng so sánh này giúp bạn dễ dàng hiểu rõ các điểm khác biệt và chọn lựa phù hợp hơn!",
      "trial_data": [
        {
          "nct_id": "NCT02380729",
          "title": "Mutation Exploration in Non-acquired, Genetic Disorders and Its Impact on Health Economy and Life Quality",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          1. Diagnosis: Suspicion of genetic disease. (Only one of the following criteria is\r\n             required.) [1.1] Family member(s) with similar phenotype OR [1.2] At least two\r\n             affected organ systems OR [1.3] One affected organ system that is known to be\r\n             associated with multiple disease causing genes (e.g. long QT syndrome) OR [1.4]\r\n             Multiple birth defects\r\n\r\n          2. Both parents must be available for blood draw in order to confirm phase (segregation\r\n             analysis) or in order to perform WGS of the trio at a later time point.\r\n\r\n          3. Age: from birth up until age 18 years\r\n\r\n          4. Gender: Both sexes will be included\r\n\r\n        Exclusion Criteria:\r\n\r\n          1. Suspicion that the phenotype is due to an acquired disease\r\n\r\n          2. Missing informed consent from both parents or from all legal guardians for genetic\r\n             testing in the setting of a clinical trial.\r\n\r\n          3. Clinical diagnosis of a disease with a known monogenic cause, e.g. Phenylketonuria or\r\n             Cystic fibrosis.",
          "brief_summary": "The MENDEL-study will investigate whether the use of gene panel or whole genome sequencing\r\n      (WGS) will:\r\n\r\n        1. improve the rate of diagnosis and through this compare the performance of the two\r\n           diagnostic approaches (gene panel vs. WGS),\r\n\r\n        2. investigate whether use of said sequencing approaches early in the diagnostic process\r\n           results in reduced health care spending, and\r\n\r\n        3. result in an improved quality of life for the patients and their parents.",
          "detailed_description": "Patients will be recruited from in- and outpatient clinics at the Otto Heubner Center, the\r\n      Berlin Center for Rare Diseases, and the Institute for Medical Genetics and Human Genetics at\r\n      Charité-Universitätsmedizin Berlin, Germany. Following informed consent, 5 ml EDTA blood will\r\n      be obtained from the index case and 10 ml blood from each parent. Disease related phenotype\r\n      information and the outcome of previous diagnostic tests and procedures will be recorded as\r\n      part of Study visit #1.\r\n\r\n      [1] Study visit #1\r\n\r\n        1. A medical genetics physical will be performed. Detailed clinical symptoms (phenotype)\r\n           will be recorded using Human Phenotype Ontology (HPO) terminology.\r\n\r\n        2. A detailed pedigree will be drawn.\r\n\r\n        3. Age of disease onset will be determined.\r\n\r\n        4. Results from previous diagnostic tests and procedures, as well as hospital stays, will\r\n           be recorded.\r\n\r\n        5. The parents will be asked to complete a validated, standardized quality of life\r\n           questionnaire adapted for for rare disease. The questionnaire is available online or in\r\n           paper form.\r\n\r\n      [2] Study visit #2a (optional)\r\n\r\n      This study visit will only take place in the event that gene panel sequencing identifies a\r\n      variant of uncertain significance, where additional information would be needed in order to\r\n      determine its pathogenicity (e.g. confirmational biochemical testing, collection of\r\n      additional information). Relevant research findings will be discussed and the nature and\r\n      necessity of the additional testing will be explained.\r\n\r\n      [3] Study visit #2b (optional)\r\n\r\n      This study visit will only take place in the event that WGS identifies a variant of uncertain\r\n      significance where additional information is needed in order to determine its pathogenicity >\r\n      see Study visit #2a.\r\n\r\n      [4] Study visit #3 (results session)\r\n\r\n      Results will be returned in the context of a genetic counseling session.\r\n\r\n      [5] Study visit #4 (6 months after Study visit #3)\r\n\r\n      The parents will be asked to complete the validated, standardized quality of life\r\n      questionnaire adapted for rare disease again.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT04184817",
          "title": "Radiological Analysis on Patients With Achondroplasia Disorder",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Boys and girls.\r\n\r\n          -  Aged from 0 to 18 years old.\r\n\r\n          -  Subjects with an Achondroplasia diagnosis.\r\n\r\n          -  Patients or parents/ legal guardian must provide non opposition prior to participation\r\n             in the study.\r\n\r\n        Exclusion Criteria:\r\n\r\n        - Patients or patient's parents or legal guardian whose have an objection for using their\r\n        data.",
          "brief_summary": "Achondroplasia is a genetic disorder characterized by disproportionate short stature. It\r\n      affects about 1 in 2500 live births in the world. The cause of Achondroplasia was identified\r\n      to be a gain-of-function mutations in the fibroblast growth receptor 3 (FGFR3). In these\r\n      children compression of the spinal cord at the foramen magnum stenosis can occur in early\r\n      childhood which, can lead to central sleep apnea. It can lead to morbidity and mortality. A\r\n      surgical intervention may be indicated in patients who present a foramen magnum stenosis.\r\n      However, surgical indications are still under discussion. The objective of this retrospective\r\n      study is to analyse the degree of stenosis and its clinical tolerance/evolution from\r\n      radiological data monitored at the Hospital Femme Mère Enfant.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 7.904693,
      "language": "vi",
      "llm_scores": {
        "hallucination": 2,
        "hallucination_reasoning": "Several specific details are not supported by the provided trial information. Examples: claiming NCT02380729 is at Charité in Berlin and NCT04184817 is at Hospital Femme Mère Enfant in France (locations not given in the excerpt); asserting no special travel is required and only local blood draw; stating NCT04184817 only uses existing imaging data and needs no follow‑up; summarizing exclusion for NCT02380729 as just “phản ứng với bệnh do nguyên nhân khác” and “không có sự đồng ý,” which oversimplifies and partly distorts the detailed criteria. These are speculative additions beyond the text.",
        "accuracy": 3,
        "accuracy_reasoning": "Core distinctions are mostly right (genetic diagnostic study vs radiological retrospective study; both include boys and girls 0–18; different target populations and objectives). However, there are notable inaccuracies/oversimplifications: exclusion criteria for NCT02380729 are reduced to two vague items, omitting important details (acquired disease, known monogenic diagnosis, informed consent); the description of NCT04184817’s purpose as only ‘đánh giá mức độ hẹp ống sống’ is a partial restatement (trial text focuses on foramen magnum stenosis and its clinical tolerance/evolution). Statements on travel, visit frequency, and duration are speculative and not grounded in the provided info.",
        "clarity": 5,
        "clarity_reasoning": "The comparison is well structured in a clear table with headings by criterion, then a concise summary of key differences and simple ‘gợi ý’ to help with decision‑making. It is patient‑friendly and easy to follow.",
        "language_correction": 5,
        "language_correction_reasoning": "User wrote in Vietnamese; the response is consistently in Vietnamese with appropriate terminology and no language mixing."
      }
    },
    {
      "topic_number": "35",
      "trial_ids": [
        "NCT02524470",
        "NCT00245921",
        "NCT04003662"
      ],
      "query": "So sánh các thử nghiệm này: NCT02524470, NCT00245921, NCT04003662",
      "response": "Dưới đây là so sánh rõ ràng giữa ba thử nghiệm lâm sàng: NCT02524470, NCT00245921, và NCT04003662. Tôi đã trình bày các điểm chính để giúp bạn dễ dàng hiểu sự khác biệt và phù hợp với nhu cầu của bạn.\n\n| **Yếu tố so sánh**                     | **NCT02524470: Vital Signs Patch Early Feasibility** | **NCT00245921: Oral Contraceptive Study** | **NCT04003662: Vital Sign Comparison with AI** |\n|----------------------------------------|-----------------------------------------------------|------------------------------------------|------------------------------------------------|\n| **Phân loại thử nghiệm (Phase)**      | Không xác định (N/A)                                | Không xác định (N/A)                     | Không xác định (N/A)                           |\n| **Loại điều trị / can thiệp**          | Đeo miếng dán theo dõi dấu hiệu sinh tồn trong bệnh viện | Thuốc tránh thai kết hợp LNG/EE          | Phần mềm AI đo dấu hiệu sinh tồn qua camera  |\n| **Yêu cầu về địa điểm**                 | Bệnh viện, trong môi trường nội trú               | Không yêu cầu đặc biệt, chỉ cần tham gia theo lịch trình | Không yêu cầu đặc biệt, có thể dùng tại nhà hoặc nơi có thiết bị điện tử |\n| **Tần suất khám / theo dõi**            | Tối thiểu 3 ngày, có thể đến 7 ngày trong bệnh viện | Không xác định rõ, thường theo lịch trình thuốc | Thường xuyên, hai lần đo cùng lúc, qua camera |\n| **Điều kiện tham gia chính**             | Người lớn, bệnh nhân nội trú, có dấu hiệu sinh tồn ổn định | Phụ nữ khỏe mạnh, 18-49 tuổi, chu kỳ đều đặn | Người đủ khả năng đọc tiếng Anh, có thiết bị điện tử, sẵn sàng hợp tác |\n| **Yêu cầu về thời gian tham gia**       | Theo dõi trong 3-7 ngày bệnh viện                  | Không rõ, liên quan đến chu kỳ kinh nguyệt | Không rõ, dự kiến ngắn, chỉ cần chụp hình và làm theo hướng dẫn |\n| **Tình trạng hiện tại của thử nghiệm** | Không rõ (N/A)                                      | Không rõ (N/A)                           | Không rõ (N/A)                                |\n| **Yếu tố đặc biệt / khác biệt chính**  | Đánh giá tính khả thi của miếng dán theo dõi sinh tồn trong bệnh viện | Đánh giá hiệu quả thuốc tránh thai | Phát triển AI để đo dấu hiệu sinh tồn qua camera, không cần thiết bị chuyên dụng |\n\n### Điểm nổi bật và so sánh:\n- **NCT02524470** tập trung vào thử nghiệm công nghệ mới (dán theo dõi sinh tồn) trong bệnh viện, phù hợp nếu bạn muốn tham gia vào nghiên cứu về công nghệ y tế.\n- **NCT00245921** là thử nghiệm thuốc tránh thai, dành cho phụ nữ khỏe mạnh, không yêu cầu đi lại nhiều, phù hợp nếu bạn quan tâm đến kiểm soát sinh sản.\n- **NCT04003662** là thử nghiệm công nghệ AI đo dấu hiệu sinh tồn qua camera, có thể tham gia tại nhà hoặc bất cứ nơi nào có thiết bị điện tử, phù hợp nếu bạn thích thử nghiệm công nghệ mới và không muốn đi lại nhiều.\n\n### Đề xuất:\n- Nếu bạn muốn tham gia thử nghiệm liên quan đến công nghệ y tế trong bệnh viện, NCT02524470 hoặc NCT04003662 có thể phù hợp.\n- Nếu bạn quan tâm đến thuốc tránh thai và không muốn đi lại nhiều, NCT00245921 là lựa chọn phù hợp.\n- Nếu bạn thích thử nghiệm công nghệ mới, không cần đi lại nhiều, NCT04003662 có thể là lựa chọn tốt nhất.\n\nNếu bạn cần giúp chọn thử nghiệm phù hợp hơn dựa trên lịch trình hoặc sở thích cá nhân, tôi sẵn sàng giúp đỡ thêm!",
      "trial_data": [
        {
          "nct_id": "NCT02524470",
          "title": "Vital Signs Patch Early Feasibility and Usability Study v1.0",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Adult male and female in-patients with vital signs considered 'stable' by clinical\r\n             caregivers.\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Pediatric patients\r\n\r\n          -  Female patients who are pregnant\r\n\r\n          -  Patients with internal or external defibrillators\r\n\r\n          -  Patients who have undergone surgery and still have a fresh incision on the chest.\r\n\r\n          -  Patients with skin damage on the chest such as burns, irritation, infections, wounds,\r\n             etc.\r\n\r\n          -  Patients in the Critical Care Unit (CCU)\r\n\r\n          -  Patients who otherwise satisfy any of the contraindications associated with the VSP\r\n             system.",
          "brief_summary": "To assess the feasibility and usability of the Vital Signs Patch (VSP) System in the\r\n      in-patient hospital setting to monitor vital signs using a patch, brain, gateway, and\r\n      console. The VSP System will be incorporated into the study site's Information Technology\r\n      infrastructure.",
          "detailed_description": "The primary objective of this clinical feasibility study is to evaluate the feasibility of\r\n      the Vital Signs Patch System (VSP). The VSP will be incorporated into the study site's\r\n      Information Technology infrastructure and worn by in-patients for a minimum of 3 days and for\r\n      the duration of their hospital stay up to 7 days.\r\n\r\n      The VSP will take and monitor vital signs in addition to the normal equipment the facility\r\n      uses to monitor and take vital signs. This study will not be assessing safety and no\r\n      comparator groups will be used. As this study will not be treating any particular disease or\r\n      condition, no randomization or blinding is required. Subjects will be chosen as they are\r\n      admitted in accordance with the general population characteristics, inclusion and exclusion\r\n      criteria and willingness to sign the Informed Consent.\r\n\r\n      This clinical study involves a device with no additional drugs administered.\r\n\r\n      During this study, a single VSP System patch will be worn for up to 48 hours. The first patch\r\n      will be placed using the NEHB configuration. After the first 48 hours, the NEHB-configured\r\n      patch will be replaced with a new patch in the PAL configuration. The second patch can remain\r\n      on the subject for the duration of the subject's hospital stay, or up to seven (7)\r\n      consecutive days. Individual patient use will determine the duration of time that the second\r\n      patch can be worn.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT00245921",
          "title": "Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Healthy women aged 18 to 49 years\r\n\r\n          -  Regular (21- to 35- day) menstrual cycles for the 3-month period preceding visit 1\r\n\r\n          -  Must be sexually active and at risk for becoming pregnant.\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Planned use of any other form of birth control other than the test article.\r\n\r\n          -  Depression requiring hospitalization or associated with suicidal ideation within the\r\n             last 3 years.\r\n\r\n          -  High blood pressure (defined as elevated sitting blood pressure: > 140/90 mm Hg).",
          "brief_summary": "To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a\r\n      combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT04003662",
          "title": "Vital Sign Comparison Between Lifelight and Standard of Care - Development",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  I1. Sufficiently conversant in the English language to satisfy I3.\r\n\r\n          -  I2. Able and willing to comply with all study requirements.\r\n\r\n          -  I3. Able and willing to provide written informed consent to participate (including by\r\n             parent or legal guardian if under 16 years old).\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  There are no exclusion criteria.",
          "brief_summary": "Patients and volunteers both with and without medical problems will be recruited; vital sign\r\n      measurements are taken twice with normal equipment and while recording video data at the same\r\n      time. The data collected will allow the Artificial Intelligence to develop the LifeLight\r\n      algorithm to to improve measurement accuracy of its video data based vital signs monitor.",
          "detailed_description": "Vital signs such as heart rate, blood pressure, breathing rate and oxygen levels currently\r\n      need several pieces of equipment and trained staff in order to be measured properly. The\r\n      LifeLight app measures the same vital signs using a camera in a phone, tablet, laptop or\r\n      smart TV. By using very small changes in the colour of your skin, LifeLight's AI system can\r\n      calculate these values without any extra equipment or training, and without contact.\r\n\r\n      The aim of this research study is to improve the accuracy of the LifeLight system with a view\r\n      to a subsequent Validation study to prove the level of accuracy. The investigators will\r\n      recruit patients, staff and visitors, both with and without medical problems, and take vital\r\n      sign measurements twice with normal equipment and while recording video data at the same\r\n      time. This will allow the AI which develops the LifeLight algorithm to make it more accurate,\r\n      prior to a subsequent study which will validate the results.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 8.176435,
      "language": "vi",
      "llm_scores": {
        "hallucination": 2,
        "hallucination_reasoning": "Nhiều chi tiết không hề xuất hiện trong mô tả thử nghiệm: thời gian tham gia 3–7 ngày nội trú cho NCT02524470, tần suất khám hoặc theo dõi cụ thể, khả năng tham gia NCT04003662 \"tại nhà hoặc bất cứ nơi nào có thiết bị điện tử\" và yêu cầu \"có thiết bị điện tử\", cũng như nhận định NCT00245921 \"không yêu cầu đi lại nhiều\" đều là suy đoán, không được nêu trong thông tin gốc. Do đó có nhiều yếu tố bịa thêm/diễn giải quá mức.",
        "accuracy": 2,
        "accuracy_reasoning": "Dù phân biệt đúng một số điểm lớn (loại can thiệp: miếng dán theo dõi, thuốc tránh thai, AI đo sinh hiệu; đối tượng: bệnh nhân nội trú ổn định, phụ nữ khỏe mạnh, người có thể nói tiếng Anh và đồng ý tham gia), nhưng có nhiều diễn giải sai hoặc vượt quá dữ liệu: yêu cầu địa điểm và khả năng tham gia tại nhà cho NCT04003662 không được nêu; thời lượng và tần suất theo dõi của NCT02524470 và NCT04003662 không được mô tả trong trial info; mức độ \"không cần đi lại nhiều\" cho NCT00245921 không có trong mô tả; ghi chú \"có thiết bị điện tử\" là điều kiện tham gia không có trong tiêu chí. So sánh chưa phản ánh chính xác mức độ đòi hỏi thực tế vì thiếu thông tin, nhưng lại đưa kết luận khẳng định.",
        "clarity": 4,
        "clarity_reasoning": "Bố cục rõ ràng, dùng bảng so sánh với các yếu tố quan trọng (loại can thiệp, điều kiện tham gia, yêu cầu địa điểm, thời gian) và có phần tóm tắt, gợi ý lựa chọn, khá dễ hiểu và thân thiện với bệnh nhân. Tuy nhiên, vì một số thông tin trong bảng là suy đoán, người đọc có thể hiểu nhầm đây là dữ kiện chính thức, làm giảm tính hữu ích thực tế của độ rõ ràng.",
        "language_correction": 5,
        "language_correction_reasoning": "Người dùng hỏi bằng tiếng Việt và câu trả lời hoàn toàn bằng tiếng Việt, dùng thuật ngữ y khoa phù hợp, không pha trộn ngôn ngữ khác đáng kể."
      }
    },
    {
      "topic_number": "6",
      "trial_ids": [
        "NCT02024113",
        "NCT00172835"
      ],
      "query": "So sánh các thử nghiệm này: NCT02024113, NCT00172835",
      "response": "Dưới đây là so sánh rõ ràng giữa hai thử nghiệm lâm sàng NCT02024113 và NCT00172835, giúp bạn dễ dàng hiểu các điểm khác biệt và giống nhau để đưa ra quyết định phù hợp:\n\n| **Tiêu chí**                     | **NCT02024113: Nghiên cứu về các dấu hiệu sinh học để phát hiện ung thư phổi** | **NCT00172835: Sử dụng Procalcitonin trong chẩn đoán tràn dịch màng phổi** |\n|----------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------|\n| **Giai đoạn thử nghiệm**         | Không xác định (N/A)                                                            | Không xác định (N/A)                                                      |\n| **Loại can thiệp**                | Phân tích các mẫu máu bằng phương pháp NMR để xác định đặc điểm chuyển hóa của ung thư phổi | Đo mức procalcitonin trong máu để chẩn đoán nhiễm trùng do vi khuẩn trong tràn dịch màng phổi |\n| **Địa điểm thực hiện**            | Thường tại các trung tâm y tế có trang thiết bị NMR, liên quan đến chẩn đoán hình ảnh | Thường tại các bệnh viện hoặc trung tâm y tế có khả năng xét nghiệm máu và dịch màng phổi |\n| **Yêu cầu về số lần khám**        | Không rõ, có thể chỉ cần lấy mẫu máu một lần hoặc theo kế hoạch nghiên cứu | Thường chỉ cần lấy mẫu máu hoặc dịch màng phổi một lần để xét nghiệm |\n| **Tiêu chí tham gia chính**       | - Người mới chẩn đoán ung thư phổi, chưa điều trị trước đó<br>- Không có tiền sử ung thư trong 5 năm gần nhất<br>- Không đói ít nhất 6 giờ trước xét nghiệm<br>- Không dùng thuốc trong ngày xét nghiệm<br>- Không mắc bệnh tiểu đường nặng (glucose ≥ 200 mg/dl) | - Có chẩn đoán tràn dịch màng phổi<br>- Tràn dịch đã được xác nhận bằng siêu âm<br>- Không có điều kiện chống chỉ định chọc dò dịch màng phổi hoặc mang thai |\n| **Yêu cầu về thời gian và cam kết** | Không rõ, có thể liên quan đến việc lấy mẫu và theo dõi qua nhiều bước | Thường chỉ cần một lần lấy mẫu, thời gian ngắn hơn |\n| **Tình trạng thử nghiệm**          | Thông tin không rõ (N/A)                                                        | Thông tin không rõ (N/A)                                                  |\n| **Điểm đặc biệt khác**             | Tập trung vào phát hiện sớm ung thư phổi qua phân tích chuyển hóa máu | Tập trung vào chẩn đoán nhiễm trùng trong tràn dịch màng phổi bằng xét nghiệm máu |\n\n### So sánh tổng quát:\n- **NCT02024113** là nghiên cứu về phát hiện ung thư phổi sớm qua phân tích các chất chuyển hóa trong máu, phù hợp với những người mới chẩn đoán ung thư phổi và chưa điều trị.\n- **NCT00172835** tập trung vào chẩn đoán nhiễm trùng trong tràn dịch màng phổi bằng xét nghiệm procalcitonin, phù hợp với những người có tràn dịch màng phổi đã xác nhận.\n\n### Đề xuất:\n- Nếu bạn quan tâm đến việc phát hiện ung thư phổi sớm, thử nghiệm NCT02024113 có thể phù hợp.\n- Nếu bạn đang điều trị hoặc chẩn đoán tràn dịch màng phổi, thử nghiệm NCT00172835 có thể phù hợp hơn.\n\nNếu bạn muốn biết thêm về yêu cầu cụ thể hoặc mức độ \"đòi hỏi\" của từng thử nghiệm, tôi sẵn sàng giúp đỡ!",
      "trial_data": [
        {
          "nct_id": "NCT02024113",
          "title": "LC-NMR Study Biomarkers to Detect Lung Cancer",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Diagnosis of a new lesion in the lung\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  a prior diagnosis of cancer in the past\r\n\r\n          -  Not fasted for at least 6 hours\r\n\r\n          -  Plasma glucose concentration ≥ 200 mg/dl\r\n\r\n          -  Intake of medication at the day of investigation\r\n\r\n          -  History/treatment of cancer in the previous 5 years",
          "brief_summary": "Lung cancer is the most common cancer in men and the fourth most common cancer in women\r\n      worldwide. Until today no effective method permits the early detection of lung cancer.\r\n      Consequently, lung cancer is often diagnosed owing to symptoms of advanced disease. To\r\n      address this problem, detection methods with an improved sensitivity and specificity are\r\n      urgently needed.\r\n\r\n      Over the past decade, accumulating evidence shows that the metabolism of cancer cells differs\r\n      from that of normal cells. More specifically, the entire metabolism of cancer cells is\r\n      reorganized or reprogrammed to increase anabolic reactions that induce cell growth and\r\n      survival. Metabolic reprogramming during the development of cancer is driven by aberrant\r\n      signaling pathways due to the activation of oncogenes and the loss of tumor suppressor genes.\r\n      Furthermore, the microenvironment of the tumor plays a role in metabolic reprogramming. The\r\n      altered cancer metabolism is characterized by an increased glycolysis, the production of\r\n      lactate and the biosynthesis of macromolecules, such as proteins, lipids and nucleotides.\r\n      Cancer cells have a high glycolytic rate and eliminate most of the glucose-derived carbon as\r\n      lactate rather than oxidizing it completely via oxidative phosphorylation, a phenomenon known\r\n      as the Warburg effect. The breakdown of glucose and other nutrients leads to a high energy\r\n      production and provides the Krebs cycle with intermediates, which consequently are allocated\r\n      to metabolic pathways that support biosynthesis. Metabolites are the end products of cellular\r\n      metabolism and are therefore closely related to the observed phenotype. Disturbances in\r\n      biochemical pathways which occur during the development of cancer consequently provoke\r\n      changes in the metabolic phenotype. As a result, low-molecular weight metabolites are very\r\n      attractive biomarkers for different cancer types. Nuclear magnetic resonance (NMR)\r\n      spectroscopy enables the identification and quantitative analysis of complex mixtures of\r\n      metabolites, as in plasma and serum, without an extended sample preparation.\r\n\r\n      The present study aims to determine the metabolic phenotype of lung cancer by means of proton\r\n      (1H)-NMR spectroscopy. Once the phenotype determined (training cohort), this has to be\r\n      validated by an independent cohort.",
          "detailed_description": "Subjects Subjects with lung cancer detected by a computed tomography (CT)-scan and referred\r\n      to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is\r\n      confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology\r\n      with respect to radiological or clinical data. The control group consists of subjects who\r\n      were referred to the department Nuclear Medicine for an examination of the heart. This\r\n      control group represents the average population, consists of healthy subjects and patients\r\n      with non-cancer diseases and did not undergo a PET/CT-scan. Exclusion criteria are as\r\n      follows: (1) not fasted for at least 6 hours, (2) poorly controlled diabetes (fasting plasma\r\n      glucose concentration ≥ 200 mg/dl) in cancer patients, (3) medication intake at the day of\r\n      blood sampling and (4) treatment or history of cancer in the preceding 5 years.\r\n\r\n      The training cohort consists of 80 subject with lung cancer and 80 controls. The validation\r\n      cohort consist of 250 subject with lung cancer and 250 controls.\r\n\r\n      Blood sampling and processing Fasting venous blood samples (BD Vacutainer® LH 17 I.U. 10 ml\r\n      tube) are collected and stored at 4°C within 5 to 10 minutes. Around 8 hours after blood\r\n      collection, blood samples are transported on crushed ice to the central laboratory and\r\n      centrifuged at room temperature (swinging bucket centrifuge, 1600 g, 15 minutes).\r\n      Subsequently, 4 plasma aliquots of 500 µl are transferred into sterile cryovials and stored\r\n      at -80°C until examination within 6 months. When subjects give permission to store their\r\n      biological material, 3 aliquots are stored at the University Biobank Limburg (UBiLim) for\r\n      biomedical research purposes.\r\n\r\n      Prior to NMR analysis, plasma aliquots are thawed and homogenized using a vortex mixer. After\r\n      centrifugation at 13000 g for 4 minutes at 4°C (fixed rotor Eppendorf centrifuge 5415 R,\r\n      Hamburg, Germany), plasma aliquots are diluted in deuterium oxide (D2O, 99.9%, Cambridge\r\n      Isotope Laboratories Inc, Andover, USA) containing 180 µg/µl\r\n      trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP, 98%, Cambridge Isotope Laboratories\r\n      Inc, Andover, USA) as a chemical shift reference. Finally, the prepared plasma samples are\r\n      transferred into a 5 mm NMR tube and analyzed.\r\n\r\n      1H-NMR analyses and assignment of present resonances The 1H-NMR spectra are recorded on a 400\r\n      Megahertz (MHz) NMR spectrometer (Varian/Agilent, Nuclear Magnetic Resonance Instruments,\r\n      Palo Alto, California, USA) with a magnetic field strength of 9.4 Tesla at 294 K. Slightly\r\n      T2- weighted spectra are acquired using a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence to\r\n      attenuate signals of macromolecules, such as proteins and polysaccharides. Additionally,\r\n      water suppression is performed in order to allow optimal detection and quantification of\r\n      low-molecular weight metabolites. The 1H-NMR spectra are phased manually, baseline corrected\r\n      and referenced to the TSP resonance at 0.015 parts per million (ppm). The assignment of the\r\n      present 1H-NMR resonances occurs by means of spiking experiments. A reference plasma sample\r\n      is alternately spiked with 34 known metabolites with a concentration of 1 mg compound per 100\r\n      µl plasma. The obtained chemical shifts are double checked with Chenomx NMR suite software\r\n      (Version 7.5, Chenomx Inc., Edmonton, Alberta, Canada). Finally, 1H-NMR spectra are divided\r\n      in 112 spectral regions, which are integrated and normalized relative to the total integrated\r\n      area of all spectral regions, irrespective of the remaining water, TSP, fructose and glucose\r\n      resonances. The end result corresponds to 110 normalized integration regions (all integration\r\n      regions except those of water and TSP).\r\n\r\n      Statistical analysis At first, the integration values of all 110 spectral regions are\r\n      analyzed by means of a student t-test with correction for multiple testing by\r\n      Benjamini-Hochberg to identify those which differ significantly between lung cancer patients\r\n      and controls (IBM SPSS Version 20.0, Chicago, Illinois, USA). Secondly, multivariate\r\n      statistical analyses are performed using SIMCA-P+ (Version 12.0, Umetrics, Umea, Sweden) to\r\n      investigate whether the metabolic composition of blood plasma allows to discriminate between\r\n      lung cancer patients and controls. An unsupervised principal component analysis (PCA) was\r\n      performed to identify intrinsic clusters and outliers within the dataset. After the removal\r\n      of outliers (detected by a Hotelling's T2 range plot), an orthogonal partial least squares\r\n      discriminant analysis (OPLS-DA), an extension of partial least squares discriminant analysis\r\n      (PLS-DA) with an integrated orthogonal signal correction filter, is performed to remove\r\n      variability not relevant to class separation. The predicted classification is expressed as\r\n      specificity (the percentage of controls that are actually classified as controls) and\r\n      sensitivity (the percentage of lung cancer patients that are actually classified as lung\r\n      cancer patients). The outcome of using the integration values of the significantly different\r\n      spectral regions, obtained by the student t-test with correction for multiple testing by\r\n      Benjamini-Hochberg, is compared to the outcome in which the integration values of all 110\r\n      spectral regions were used.",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        },
        {
          "nct_id": "NCT00172835",
          "title": "Use of Procalcitonin in the Diagnosis of Pleural Effusion",
          "phase": "N/A",
          "status": "N/A",
          "eligibility_criteria": "Inclusion Criteria:\r\n\r\n          -  Clinical diagnosis of pleural effusion\r\n\r\n          -  Pleural effusion proved by chest sonography\r\n\r\n        Exclusion Criteria:\r\n\r\n          -  Conditions for which thoracentesis are contraindicated\r\n\r\n          -  Pregnancy",
          "brief_summary": "Among several markers of inflammation and sepsis, procalcitonin (PCT) markers is being\r\n      studied to investigate their accuracy for the diagnosis of bacterial infections. PCT is the\r\n      prehormone of calcitonin, which is normally secreted by the C cells of the thyroid in\r\n      response to hypercalcemia; under these normal conditions, negligible serumPCT concentrations\r\n      are detected. The mechanism proposed for PCT production after inflammation and its role are\r\n      still not completely known. It is believed that PCT is produced by the liver and peripheral\r\n      blood mononuclear cells, modulated by lipopolysaccharides and sepsis-related cytokines. It\r\n      binds to polysaccharides in pathogens, activating the classical complement pathway. The\r\n      reported diagnostic accuracy of PCT for the diagnosis of bacterial infections has varied\r\n      across studies.",
          "detailed_description": "",
          "locations": "N/A",
          "start_date": "N/A",
          "completion_date": "N/A",
          "primary_outcome": "N/A"
        }
      ],
      "execution_time": 7.989387,
      "language": "vi",
      "llm_scores": {
        "hallucination": 3,
        "hallucination_reasoning": "Có một số chi tiết suy đoán không được nêu trong mô tả thử nghiệm: (1) Gọi NCT02024113 là nghiên cứu ở ‘người mới chẩn đoán ung thư phổi’ là không chính xác; tiêu chí chỉ ghi ‘Diagnosis of a new lesion in the lung’, chưa chắc là ung thư. (2) Nói các thử nghiệm ‘thường’ diễn ra tại trung tâm có thiết bị NMR hoặc ‘thường chỉ cần một lần lấy mẫu’ cho cả hai nghiên cứu đều là phỏng đoán, vì tài liệu không nói về địa điểm cụ thể hay số lần lấy mẫu/khám. (3) Mô tả NCT00172835 là chẩn đoán ‘nhiễm trùng trong tràn dịch màng phổi’ là diễn giải hẹp hơn so với mô tả gốc chỉ nói chung về chẩn đoán nhiễm khuẩn bằng PCT. Tuy nhiên, không có sai lệch quá nghiêm trọng về mục tiêu tổng quan của các nghiên cứu.",
        "accuracy": 3,
        "accuracy_reasoning": "Các điểm chính về mục tiêu hai nghiên cứu (dấu ấn chuyển hóa/NMR cho ung thư phổi vs procalcitonin cho tràn dịch màng phổi) được phản ánh khá đúng, cũng như tiêu chí loại trừ chính (tiền sử ung thư, glucose, thuốc, mang thai, chống chỉ định chọc dò). Tuy nhiên có những diễn giải không chính xác hoặc quá đà: (1) Nhầm nhóm đối tượng NCT02024113 là bệnh nhân ‘mới chẩn đoán ung thư phổi’ thay vì ‘tổn thương mới ở phổi’. (2) Mục tiêu của NCT00172835 được rút gọn thành ‘chẩn đoán nhiễm trùng trong tràn dịch màng phổi’, trong khi bản mô tả chỉ nói về độ chính xác PCT trong chẩn đoán nhiễm khuẩn nói chung trên bệnh nhân có tràn dịch. (3) Các nội dung về số lần khám/lấy mẫu, địa điểm và mức độ thời gian/cam kết chủ yếu là phỏng đoán, không dựa trên văn bản. Do đó độ chính xác tổng thể chỉ ở mức trung bình.",
        "clarity": 5,
        "clarity_reasoning": "Bài so sánh được trình bày rất rõ ràng, có bảng đối chiếu theo tiêu chí (giai đoạn, loại can thiệp, tiêu chí tham gia, thời gian/cam kết, điểm đặc biệt). Ngôn ngữ thân thiện, dễ hiểu cho bệnh nhân, cuối có phần tóm tắt và gợi ý khi nào nên cân nhắc mỗi thử nghiệm, giúp người đọc dễ so sánh và định hướng.",
        "language_correction": 5,
        "language_correction_reasoning": "Người dùng hỏi bằng tiếng Việt và toàn bộ phần so sánh được viết bằng tiếng Việt, nhất quán, dễ hiểu. Không có pha trộn ngôn ngữ đáng kể ngoài các từ viết tắt chuyên môn (NMR, PCT) vốn phù hợp ngữ cảnh."
      }
    }
  ],
  "average_scores": {
    "overall": {
      "hallucination": 2.7,
      "accuracy": 2.9,
      "clarity": 4.6,
      "language_correction": 4.9,
      "total_scored": 10
    }
  }
}